Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# National Centre for Pharmacoeconomics

NCPE Ireland

## Sitemaps

- [XML Sitemap](https://www.ncpe.ie/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Durvalumab (Imfinzi®). HTA ID: 25046](https://www.ncpe.ie/durvalumab-imfinzi-hta-id-25046/)
- [Acalabrutinib (Calquence®) for CLL. HTA ID: 25040](https://www.ncpe.ie/acalabrutinib-calquence-for-cll-hta-id-25040/)
- [Acalabrutinib (Calquence®) for MCL. HTA ID: 25041](https://www.ncpe.ie/acalabrutinib-calquence-for-mcl-hta-id-25041/)
- [Dupilumab (Dupixent®). HTA ID: 24035](https://www.ncpe.ie/dupilumab-dupixent-hta-id-24035/)
- [Nivolumab+relatlimab (Opdualag® ). HTA ID: 24009](https://www.ncpe.ie/nivolumabrelatlimab-opdualag-hta-id-24009/)
- [Glofitamab (Columvi®) in combination with gemcitabine and oxaliplatin. HTA ID: 25037](https://www.ncpe.ie/glofitamab-columvi-in-combination-with-gemcitabine-and-oxaliplatin-hta-id-25037/)
- [Mirvetuximab soravtansine (Elahere®). HTA ID: 24051](https://www.ncpe.ie/mirvetuximab-soravtansine-elahere-hta-id-24051/)
- [Remibrutinib (Rhapsido®) HTA ID: 26027](https://www.ncpe.ie/remibrutinib-rhapsido-hta-id-26027/)
- [Semaglutide (Wegovy®). HTA ID: 25024](https://www.ncpe.ie/semaglutide-wegovy-hta-id-25024/)
- [House Dust Mite Extract (Acarizax ®) for Allergic Rhinitis (5-65 year olds) HTA ID: 25069](https://www.ncpe.ie/house-dust-mite-extract-acarizax-for-allergic-rhinitis-5-65-year-olds-hta-id-25069/)
- [Blinatumomab (Blincyto®). HTA ID: 25052](https://www.ncpe.ie/blinatumomab-blincyto-hta-id-25052/)
- [Sodium Zirconium Cyclosilicate (Lokelma®). HTA ID: 24039](https://www.ncpe.ie/sodium-zirconium-cyclosilicate-lokelma-hta-id-24039/)
- [Lecanemab (Leqembi®). HTA ID: 24052](https://www.ncpe.ie/lecanemab-leqembi-hta-id-24052/)
- [Pembrolizumab (Keytruda®). HTA ID: 24049](https://www.ncpe.ie/pembrolizumab-keytruda-hta-id-24049/)
- [Capivasertib (Truqap®). HTA ID: 24015](https://www.ncpe.ie/capivasertib-truqap-hta-id-24015/)
- [Pembrolizumab (Keytruda®). HTA ID: 26026](https://www.ncpe.ie/pembrolizumab-keytruda-hta-id-26026/)
- [Trastuzumab deruxtecan (Enhertu®). HTA ID: 25049](https://www.ncpe.ie/trastuzumab-deruxtecan-enhertu-hta-id-25049/)
- [Tislelizumab (Tevimbra®). HTA ID: 26021](https://www.ncpe.ie/tislelizumab-tevimbra-hta-id-26021/)
- [Elafibranor (Iqirvo®). HTA ID: 25005](https://www.ncpe.ie/elafibranor-iqirvo-hta-id-25005/)
- [Pembrolizumab (Keytruda®). HTA ID: 25066](https://www.ncpe.ie/pembrolizumab-keytruda-hta-id-25066/)
- [Pembrolizumab (Keytruda®). HTA ID: 25032](https://www.ncpe.ie/pembrolizumab-keytruda-hta-id-25032/)
- [Toripalimab (Loqtorzi®). HTA ID: 26022](https://www.ncpe.ie/toripalimab-loqtorzi-hta-id-26022/)
- [Selpercatinib (Retsevmo®) for NSCLC. HTA ID: 21021](https://www.ncpe.ie/selparcatinib-retsevmo-for-nsclc-hta-id-21021/)
- [Selpercatinib (Retsevmo®) for advanced RET-mutant medullary thyroid cancer. HTA ID: 21020a](https://www.ncpe.ie/selpercatinib-retsevmo-for-advanced-ret-mutant-medullary-thyroid-cancer-hta-id-21020a/)
- [Selpercatinib (Retsevmo®) for advanced RET fusion-positive thyroid cancer. HTA ID: 21020b](https://www.ncpe.ie/selpercatinib-retsevmo-for-advanced-ret-fusion-positive-thyroid-cancer-hta-id-21020b/)
- [Linzagolix Choline (Yselty®). HTA ID: 23068](https://www.ncpe.ie/linzagolix-yselty-hta-id-23068/)
- [Aficamten (Myqorzo®). HTA ID: 26019](https://www.ncpe.ie/aficamten-myqorzo-hta-id-26019/)
- [Sacituzumab govitecan (Trodelvy®). HTA ID: 23079](https://www.ncpe.ie/sacituzumab-govitecan-trodelvy-hta-id-23079/)
- [Durvalumab (Imfinzi®). HTA ID 26014](https://www.ncpe.ie/durvalumab-imfinzi-hta-id-26014/)
- [Amivantamab (Rybrevant®) in combination with lazertinib (Lazcluze®). HTA ID: 25006](https://www.ncpe.ie/amivantamab-rybrevant-in-combination-with-lazertinib-lazcluze-hta-id-25006/)
- [Zilucoplan (Zilbrysq®). HTA ID: 26024](https://www.ncpe.ie/zilucoplan-zilbrysq-hta-id-26024/)
- [Rozanolixizumab (Rystiggo®). HTA ID: 26023](https://www.ncpe.ie/rozanolixizumab-rystiggo-hta-id-26023/)
- [Relugolix with estradiol and norethisterone acetate (Ryeqo®). HTA ID: 24018](https://www.ncpe.ie/relugolix-with-estradiol-and-norethisterone-acetate-ryeqo-hta-id-24018/)
- [Belzutifan (Welireg®). HTA ID: 25020](https://www.ncpe.ie/belzutifan-welireg-hta-id-25020/)
- [Budesonide targeted-release formulation (TRF)(Kinpeygo®). HTA ID: 26002](https://www.ncpe.ie/budesonide-targeted-release-formulation-trfkinpeygo-hta-id-26002/)
- [Dostarlimab (Jemperli®). HTA ID: 26020](https://www.ncpe.ie/dostarlimab-jemperli-hta-id-26020/)
- [Niraparib + abiraterone acetate (Akeega®). HTA ID 26008](https://www.ncpe.ie/niraparib-abiraterone-acetate-akeega-hta-id-26008/)
- [Daridorexant (Quviviq®) HTA ID: 25029](https://www.ncpe.ie/daridorexant-quviviq-hta-id-25029/)
- [Acalabrutinib (Calquence®). HTA ID: 20063](https://www.ncpe.ie/acalabrutinib-calquence-hta-id-20063/)
- [Avatrombopag (Doptelet®). HTA ID: 20058](https://www.ncpe.ie/avatrombopag-doptelet-hta-id-20058/)
- [Delafloxacin (Quofenix®). HTA ID: 20038](https://www.ncpe.ie/delafloxacin-quofenix-hta-id-20038/)
- [Durvalumab (Imfinzi®). HTA ID: 26018](https://www.ncpe.ie/durvalumab-imfinzi-hta-id-26018/)
- [Ribociclib (Kisqali®). HTA ID: 24045](https://www.ncpe.ie/ribociclib-kisqali-hta-id-24045/)
- [Nusinersen 50mg/28mg (Spinraza®). HTA ID: 26016](https://www.ncpe.ie/nusinersen-50mg-28mg-spinraza-hta-id-26016/)
- [Faricimab (Vabysmo®). HTA ID: 26015](https://www.ncpe.ie/faricimab-vabysmo-hta-id-26015/)
- [Delgocitinib (Anzupgo®). HTA ID 26006](https://www.ncpe.ie/delgocitinib-anzupgo-hta-id-26006/)
- [Vorasidenib (Voranigo®). HTA ID: 25059](https://www.ncpe.ie/vorasidenib-voranigo-hta-id-25059/)
- [Major milestone under the EU HTA Regulation: First Joint clinical assessment of benefit complete.](https://www.ncpe.ie/major-milestone-under-the-eu-hta-regulation-first-joint-clinical-assessment-of-benefit-complete/)
- [Subcutaneous pembrolizumab (Keytruda®). HTA ID 26004](https://www.ncpe.ie/subcutaneous-pembrolizumab-keytruda-hta-id-26004/)
- [Infliximab (Remsima SC®) induction phase of treatment in patients with rheumatoid arthritis. HTA ID: 26017](https://www.ncpe.ie/infliximab-remsima-sc-induction-phase-of-treatment-in-patients-with-rheumatoid-arthritis-hta-id-26017/)
- [Update to the Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations v3.4](https://www.ncpe.ie/update-to-the-guidelines-for-inclusion-of-drug-costs-in-pharmacoeconomic-evaluations-v3-4/)
- [Durvalumab (Imfinzi®). HTA ID: 26012](https://www.ncpe.ie/durvalumab-imfinzi-hta-id-26012/)
- [Seladelpar (Lyvdelzi®). HTA ID: 26003](https://www.ncpe.ie/seladelpar-lyvdelzi-hta-id-26003/)
- [Fezolinetant (Veoza™). HTA ID: 24005](https://www.ncpe.ie/fezolinetant-veoza-hta-id-24005/)
- [Trastuzumab Deruxtecan (Enhertu®). HTA ID: 25039](https://www.ncpe.ie/trastuzumab-deruxtecan-enhertu-hta-id-25039/)
- [Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®). HTA ID 26011](https://www.ncpe.ie/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy-hta-id-26011/)
- [Birch bark extract (Filsuvez®). HTA ID: 23069](https://www.ncpe.ie/birch-bark-extract-filsuvez-hta-id-23069/)
- [Budesonide suppository (Budenofalk®). HTA ID: 26013](https://www.ncpe.ie/budesonide-suppository-budenofalk-hta-id-26013/)
- [Update to the Budget Impact Model Template](https://www.ncpe.ie/update-to-the-budget-impact-model-template/)
- [Tislelizumab (Tevimbra®) NSQ NSCLC. HTA ID 26009](https://www.ncpe.ie/tislelizumab-tevimbra-nsq-nsclc-hta-id-26009/)
- [Tislelizumab (Tevimbra®) SQ NSCLC. HTA ID 26010](https://www.ncpe.ie/tislelizumab-tevimbra-sq-nsclc-hta-id-26010/)
- [Ravulizumab (Ultomiris®). HTA ID: 25013](https://www.ncpe.ie/ravulizumab-ultomiris-hta-id-25013/)
- [Decitabine/cedazuridine (Inaqovi®). HTA ID 26007](https://www.ncpe.ie/decitabine-cedazuridine-inaqovi-hta-id-26007/)
- [Durvalumab (Imfinzi®). HTA ID: 25010](https://www.ncpe.ie/durvalumab-imfinzi-hta-id-25010/)
- [Maralixibat (Livmarli®). HTA ID: 25001](https://www.ncpe.ie/maralixibat-livmarli-hta-id-25001/)
- [Tislelizumab (Tevimbra®). HTA ID: 25014](https://www.ncpe.ie/tislelizumab-tevimbra-hta-id-25014/)
- [Pegcetacoplan (Aspaveli®). HTA ID: 21064](https://www.ncpe.ie/pegcetacoplan-aspaveli-hta-id-21064/)
- [Ravulizumab (Ultomiris®). HTA ID: 20036](https://www.ncpe.ie/ravulizumab-ultomiris-hta-id-20036/)
- [Ravulizumab (Ultomiris®). HTA ID: 19054](https://www.ncpe.ie/ravulizumab-ultomiris-for-the-treatment-of-adult-patients-with-paroxysmal-nocturnal-haemoglobinuria-pnh-hta-id-19054/)
- [Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®). HTA ID: 23073](https://www.ncpe.ie/tremelimumab-imjudo-in-combination-with-durvalumab-imfinzi-hta-id-23073/)
- [Axicabtagene ciloleucel (Yescarta®). HTA ID: 22066](https://www.ncpe.ie/axicabtagene-ciloleucel-yescarta-2/)
- [Faricimab (Vabysmo ®) for visual impairment due to diabetic macular oedema. HTA ID: 22061](https://www.ncpe.ie/faricimab-vabysmo-for-visual-impairment-due-to-diabetic-macular-oedema-hta-id-22061/)
- [Faricimab (Vabysmo ®) for neovascular (wet) age-related macular degeneration. HTA ID: 22060](https://www.ncpe.ie/faricimab-vabysmo-for-neovascular-wet-age-related-macular-degeneration-hta-id22060/)
- [Liraglutide (Saxenda®) in adolescent patients. HTA ID: 24001](https://www.ncpe.ie/liraglutide-saxenda-in-adolescent-patients-hta-id-24001/)
- [Crovalimab (Piasky®). HTA ID: 24027](https://www.ncpe.ie/crovalimab-piasky-hta-id-24027/)
- [Nivolumab (Opdivo®) for advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma (1L). HTA ID: 21049](https://www.ncpe.ie/nivolumab-opdivo-for-advanced-or-metastatic-gastric-gastro-oesophageal-junction-or-oesophageal-adenocarcinoma-1l-hta-id-21049/)
- [Pembrolizumab (Keytruda®). HTA ID: 24013](https://www.ncpe.ie/pembrolizumab-keytruda-hta-id-24013/)
- [Amivantamab (Rybrevant®). HTA ID: 24032](https://www.ncpe.ie/amivantamab-rybrevant-hta-id-24032/)
- [Givinostat (Duvyzat®). HTA ID: 25048](https://www.ncpe.ie/givinostat-duvyzat-hta-id-25048-2/)
- [Sotatercept (Winrevair ®). HTA ID: 24041](https://www.ncpe.ie/sotatercept-winrevair-hta-id-24041/)
- [Ruxolitinib (Opzelura®). HTA ID: 25004](https://www.ncpe.ie/ruxolitinib-opzelura-hta-id-25004/)
- [Odevixibat (Kayfanda®). HTA ID: 26005](https://www.ncpe.ie/odevixibat-kayfanda-hta-id-26005/)
- [Tirzepatide (Mounjaro®). HTA ID: 24024](https://www.ncpe.ie/tirzepatide-mounjaro-hta-id-24024/)
- [Pembrolizumab (Keytruda®). HTA ID: 23078](https://www.ncpe.ie/pembrolizumab-keytruda-hta-id-23078/)
- [Donanemab (Kisunla®). HTA ID: 25067](https://www.ncpe.ie/donanemab-kisunla-hta-id-25067/)
- [Amivantamab (Rybrevant®). HTA ID: 24044](https://www.ncpe.ie/amivantamab-rybrevant-in-combination-with-carboplatin-and-pemetrexed-hta-id-24044/)
- [Trastuzumab deruxtecan (Enhertu®). HTA ID: 24028](https://www.ncpe.ie/trastuzumab-deruxtecan-enhertu-hta-id-24028/)
- [Pegylated Liposomal irinotecan (Onivyde). HTA ID: 24030](https://www.ncpe.ie/pegylated-liposomal-irinotecan-onivyde-hta-id-24030/)
- [Pembrolizumab (Keytruda®) as monotherapy for unresectable or metastatic gastric, small intestine, or biliary cancer (2L+). HTA ID: 23058](https://www.ncpe.ie/pembrolizumab-keytruda-as-monotherapy-for-unresectable-or-metastatic-gastric-small-intestine-or-biliary-cancer-2l/)
- [Efgartigimod alfa (Vyvgart®). HTA ID: 23026](https://www.ncpe.ie/efgartigimod-alfa-vygart-hta-id-23026/)
- [Isatuximab  (Sarclisa®) in combination with carfilzomib and dexamethasone. HTA ID: 23024](https://www.ncpe.ie/isatuximab-sarclisa-in-combination-with-carfilzomib-and-dexamethasone-hta-id-23024/)
- [Olipudase alfa (Xenpozyme®). HTA ID: 23014](https://www.ncpe.ie/olipudase-alfa-xenpozyme-hta-id-23014/)
- [House dust mite allergen extract (Actair®). HTA ID: 23008](https://www.ncpe.ie/house-dust-mite-allergen-extract-actair-hta-id-23008/)
- [Melatonin (Slenyto®). HTA ID: 22048](https://www.ncpe.ie/melatonin-slenyto-hta-id-22048/)
- [Caplacizumab (Cablivi®). HTA ID: 22013](https://www.ncpe.ie/caplacizumab-cablivi-hta-id-22013/)
- [Tirzepatide (Mounjaro®). HTA ID: 24003](https://www.ncpe.ie/tirzepatide-mounjaro-hta-id-24003/)
- [Obeticholic acid (Ocaliva®)](https://www.ncpe.ie/obeticholic-acid-ocaliva/) - NCPE Pharmacoeconomic Evaluation Obeticholic acid (Ocaliva®)
- [Avapritinib (Ayvakyt®). HTA ID: 25026](https://www.ncpe.ie/avapritinib-ayvakyt-hta-id-25026/)
- [Mirikizumab (Omvoh®). HTA ID: 25068](https://www.ncpe.ie/mirikizumab-omvoh-hta-id-25068/)
- [Alpha-1 proteinase inhibitor (Prolastin®). HTA ID: 25071](https://www.ncpe.ie/alpha-1-proteinase-inhibitor-prolastin-hta-id-25071/)
- [Cabotegravir (Apretude®). HTA ID: 25072](https://www.ncpe.ie/cabotegravir-apretude-hta-id-25072/)
- [Naldemedine (Rizmoic®). HTA ID: 26001](https://www.ncpe.ie/naldemedine-rizmoic-hta-id-26001/)
- [Calcifediol monohydrate (Dnord®). HTA ID: 22063](https://www.ncpe.ie/calcifediol-monohydrate-dnord-hta-id-22063/)
- [Enfortumab vedotin in combination with pembrolizumab (Padcev® in combination with Keytruda®). HTA ID: 24038](https://www.ncpe.ie/enfortumab-vedotin-in-combination-with-pembrolizumab-padcev-in-combination-with-keytruda-hta-id-24038/)
- [Sodium thiosulfate (Pedmarqsi®). HTA ID: 25002](https://www.ncpe.ie/sodium-thiosulfate-pedmarqsi-hta-id-25002/)
- [Tezepelumab (Tezspire®). HTA ID: 23025](https://www.ncpe.ie/tezepelumab-tezspire-hta-id-23025/)
- [Dupilumab (Dupixent®) for severe asthma (children 6 to 11 years old). HTA ID: 23044](https://www.ncpe.ie/dupilumab-dupixent-for-severe-asthma-children-6-to-11-years-old-hta-id-23044/)
- [Iptacopan (Fabhalta®). HTA ID: 24023](https://www.ncpe.ie/iptacopan-fabhalta-hta-id-24023/)
- [Talquetamab (Talvey®). HTA ID: 23057](https://www.ncpe.ie/talquetamab-talvey-hta-id-23057/)
- [Epcoritamab (Tepkinly®). HTA ID: 24010](https://www.ncpe.ie/epcoritamab-tepkinly-hta-id-24010/)
- [Brexucabtagene Autoleucel (Tecartus®). HTA ID: 23045](https://www.ncpe.ie/brexucabtagene-autoleucel-tecartus-hta-id-23045/)
- [Ciltacabtagene autoleucel (Carvykti®). HTA ID: 22021](https://www.ncpe.ie/ciltacabtagene-autoleucel-carvykti-hta-id-22021/)
- [Gilteritinib (Xospata®) for Relapsed or Refractory AML. HTA ID: 19043](https://www.ncpe.ie/gilteritinib-xospata-for-relapsed-or-refractory-aml/)
- [Nivolumab (Opdivo®) with Ipilimumab (Yervoy®). HTA ID 25003](https://www.ncpe.ie/nivolumab-opdivo-with-ipilimumab-yervoy-hta-id-25003/)
- [Enalapril maleate (Aqumeldi®). HTA ID: 24011](https://www.ncpe.ie/enalapril-maleate-aqumeldi-hta-id-24011/)
- [Ivosidenib (Tibsovo®) monotherapy. HTA ID: 23016](https://www.ncpe.ie/ivosidenib-tibsovo-monotherapy-hta-id-23016/)
- [Voclosporin (Lupkynis®). HTA ID: 23003](https://www.ncpe.ie/voclosporin-lupkynis/)
- [Dupilumab (Dupixent®) for prurigo nodularis. HTA ID: 23043](https://www.ncpe.ie/dupilumab-dupixent-for-prurigo-nodularis-hta-id-23043/)
- [Durvalumab (Imfinzi®). HTA ID: 23009](https://www.ncpe.ie/durvalumab-imfinzi-2/)
- [Aztreonam-avibactam (Emblaveo®). HTA ID: 24037](https://www.ncpe.ie/aztreonam-avibactam-emblaveo-hta-id-24037/)
- [Infliximab (Remsima®) for Crohn’s disease dose escalation. HTA ID: 25022](https://www.ncpe.ie/infliximab-remsima-for-crohns-disease-dose-escalation-hta-id-25022/)
- [Obinutuzumab (Gazyvaro®). HTA ID 25065](https://www.ncpe.ie/obinutuzumab-gazyvaro-hta-id-25065/)
- [Belantamab mafodotin (Blenrep®). HTA ID: 25064](https://www.ncpe.ie/belantamab-mafodotin-blenrep-hta-id-25064/)
- [Tislelizumab (Tevimbra®). HTA ID: 25070](https://www.ncpe.ie/tislelizumab-tevimbra-hta-id-25070/)
- [Ivosidenib (Tibsovo®) in combination with azacitidine. HTA ID: 23015](https://www.ncpe.ie/ivosidenib-tibsovo-in-combination-with-azacitidine-hta-id-23015/)
- [Omaveloxolone (Skyclarys®). HTA ID: 24033](https://www.ncpe.ie/omaveloxolone-skyclarys-hta-id-24033/)
- [Ciltacabtagene autoleucel (Carvykti®). HTA ID: 24021](https://www.ncpe.ie/ciltacabtagene-autoleucel-carvykti-hta-id-24021/)
- [Polihexanide (Akantior®). HTA ID: 25045](https://www.ncpe.ie/polihexanide-akantior-hta-id-25045/)
- [Lenacapavir (Sunlenca®). HTA ID: 25047](https://www.ncpe.ie/lenacapavir-sunlenca-hta-id-25047/)
- [Inavolisib (Itovebi®). HTA ID: 25056](https://www.ncpe.ie/inavolisib-itovebi-hta-id-25056/)
- [Teprotumumab (Tepezza®). HTA ID: 25057](https://www.ncpe.ie/teprotumumab-tepezza-hta-id-25057/)
- [Metreleptin (Myalepta®). HTA ID: 25058](https://www.ncpe.ie/metreleptin-myalepta-hta-id-25058/)
- [Ritlecitinib (Litfulo®) HTA ID: 23071](https://www.ncpe.ie/ritlecitinib-litfulo-hta-id-23071/)
- [Autologous anti-CD19-transduced CD3+ cells (Tecartus®). HTA ID: 21005](https://www.ncpe.ie/autologous-anti-cd19-transduced-cd3-cells-tecartus-hta-id-21005/)
- [Lonafarnib (Zokinvy®). HTA ID: 25063](https://www.ncpe.ie/lonafarnib-zokinvy-hta-id-25063/)
- [Sparsentan (Filspari®). HTA ID: 24020](https://www.ncpe.ie/sparsentan-filspari-hta-id-24020/)
- [Risdiplam (Evrysdi®). HTA ID: 25061](https://www.ncpe.ie/risdiplam-evrysdi-hta-id-25061/)
- [Risdiplam (Evrysdi®). HTA ID: 25062](https://www.ncpe.ie/risdiplam-evrysdi-hta-id-25062/)
- [Semaglutide (Ozempic®) 2mg. HTA ID: 25060](https://www.ncpe.ie/semaglutide-ozempic-2mg-hta-id-25060/)
- [NCPE Annual Symposium 2025](https://www.ncpe.ie/annual_symposium_2025/)
- [Selpercatinib (Retsevmo®) for advanced RET fusion-positive non-small cell lung cancer. HTA ID: 25035](https://www.ncpe.ie/selpercatinib-retsevmo-for-advanced-ret-fusion-positive-non-small-cell-lung-cancer-hta-id-25035/)
- [Evolocumab (Repatha®). HTA ID:  25055](https://www.ncpe.ie/evolocumab-repatha-hta-id-25055/)
- [Tucatinib (Tukysa®). HTA ID: 22058](https://www.ncpe.ie/tucatinib-tukysa-hta-id-22058/)
- [Aflibercept (Eylea®) 8mg for DMO. HTA ID: 25053](https://www.ncpe.ie/aflibercept-eylea-8mg-for-dmo-hta-id-25053/)
- [Cabozantinib (Cabometyx®) in combination with nivolumab (Opdivo®). HTA ID: 22018](https://www.ncpe.ie/cabozantinib-cabometyx-in-combination-with-nivolumab-opdivo-for-1l-rcc-hta-id-22018/)
- [Aflibercept (Eylea®) 8mg for nAMD. HTA ID: 25054](https://www.ncpe.ie/aflibercept-eylea-8mg-for-namd-hta-id-25054/)
- [Guselkumab (Tremfya®). HTA ID: 25051](https://www.ncpe.ie/guselkumab-tremfya-hta-id-25051/)
- [Guselkumab (Tremfya®). HTA ID: 25050](https://www.ncpe.ie/guselkumab-tremfya-hta-id-25050/)
- [Dostarlimab (Jemperli®) in combination with carboplatin and paclitaxel. HTA ID: 24004](https://www.ncpe.ie/dostarlimab-jemperli-in-combination-with-carboplatin-and-paclitaxel-hta-id-24004/)
- [Zanubrutinib (Brukinsa®) for marginal zone lymphoma. HTA ID: 23072](https://www.ncpe.ie/zanubrutinib-brukinsa-for-marginal-zone-lymphoma-hta-id-23072/)
- [Pembrolizumab (Keytruda®). HTA ID: 23070](https://www.ncpe.ie/pembrolizumab-keytruda-hta-id-23070/)
- [Progesterone (Lubion®). HTA ID: 25007](https://www.ncpe.ie/progesterone-lubion-hta-id-25007/)
- [Pemigatinib (Pemazyre®). HTA ID: 24026](https://www.ncpe.ie/pemigatinib-pemazyre-hta-id-24026/)
- [Mirikizumab (Omvoh®). HTA ID: 23040](https://www.ncpe.ie/mirikizumab-omvoh-hta-id-23040/)
- [Ivacaftor/tezacaftor/elexacaftor (Kaftrio®). HTA ID: 22022](https://www.ncpe.ie/ivacaftor-tezacaftor-elexacaftor-kaftrio/)
- [Trastuzumab deruxtecan (Enhertu®). HTA ID: 23011](https://www.ncpe.ie/trastuzumab-deruxtecan-enhertu/)
- [Tisagenlecleucel (Kymriah®). HTA ID: 22044](https://www.ncpe.ie/tisagenlecleucel-kymriah-hta-id-22044/)
- [Olaparib (Lynparza®). HTA ID: 24029](https://www.ncpe.ie/olaparib-lynparza-hta-id-24029/)
- [Olaparib (Lynparza®) adjuvant treatment of early breast cancer. HTA ID: 22065](https://www.ncpe.ie/olaparib-lynparza-adjuvant-treatment-of-early-breast-cancer-hta-id-22065/)
- [Lipegfilgrastim (Lonquex®). HTA ID: 23080](https://www.ncpe.ie/lipegfilgrastim-lonquex-hta-id-23080/)
- [Bulevirtide (Hepcludex®). HTA ID: 22067](https://www.ncpe.ie/bulevirtide-hepcludex-hta-id-22067/)
- [Tenecteplase (Metalyse®): HTA ID 24046](https://www.ncpe.ie/tenecteplase-metalyse-hta-id-24046/)
- [Empagliflozin (Jardiance®). HTA ID: 24042](https://www.ncpe.ie/empagliflozin-jardiance-hta-id-24042/)
- [Fruquintinib (Fruzaqla®). HTA ID: 24031](https://www.ncpe.ie/fruquintinib-fruzaqla-hta-id-24031/)
- [Tafasitamab (Minjuvi®) in combination with lenalidomide. HTA ID: 22008](https://www.ncpe.ie/tafasitamab-minjuvi-hta-id-22008/)
- [Dupilumab (Dupixent®) for severe atopic dermatitis in children aged 6 months to 6 years old. HTA ID: 23042](https://www.ncpe.ie/dupilumab-dupixent-hta-id-23042/)
- [Erdafitinib (Balversa®). HTA ID: 24034](https://www.ncpe.ie/erdafitinib-balversa-hta-id-24034/)
- [Fenfluramine (Fintepla®) for Lennox-Gastaut Syndrome . HTA ID: 23051](https://www.ncpe.ie/fenfluramine-fintepla-for-lennox-gastaut-syndrome-hta-id-23051/)
- [Fenfluramine (Fintepla®) for Dravet Syndrome. HTA ID: 23048](https://www.ncpe.ie/fenfluramine-fintepla-for-dravet-syndrome-hta-id-23048/)
- [Estriol (Blissel®) 50 micrograms per gram. HTA ID: 22071](https://www.ncpe.ie/estriol-blissel-50-micrograms-per-gram-hta-id-22071/)
- [Teclistamab (Tecvayli®). HTA ID: 22064](https://www.ncpe.ie/teclistamab-tecvayli-hta-id-22064/)
- [Levodopa (Inbrija®). HTA ID: 25044](https://www.ncpe.ie/levodopa-inbrija-hta-id-25044/)
- [Ciclosporin (Verkazia®). HTA ID: 25042](https://www.ncpe.ie/ciclosporin-verkazia-hta-id-25042/)
- [Anifrolumab (Saphnelo®). HTA ID: 23027](https://www.ncpe.ie/anifrolumab-saphnelo-hta-id-23027/)
- [Bevacizumab gamma (Lytenava®). HTA ID: 25043](https://www.ncpe.ie/bevacizumab-gamma-lytenava-hta-id-25043/)
- [Risankizumab (Skyrizi®) HTA ID: 24025](https://www.ncpe.ie/risankizumab-skyrizi-hta-id-24025/)
- [Venetoclax (Venclyxto®) in combination with obinutuzumab (Gazyvaro®). HTA ID: 20046](https://www.ncpe.ie/venetoclax-venclyxto-in-combination-with-obinutuzumab-gazyvaro-hta-id-20046/)
- [Larotrectinib (Vitrakvi®). HTA ID: 19050](https://www.ncpe.ie/larotrectinib-viktravi-hta-id-19050/) - NCPE Pharmacoeconomic Evaluation Larotrectinib (Viktravi®)
- [Trifluridine/tipiracil (Lonsurf®) for metastatic gastric cancer. HTA ID: 22011](https://www.ncpe.ie/trifluridine-tipiracil-lonsurf-for-metastatic-gastric-cancer-hta-id-22011/)
- [Encorafenib (Braftovi®) in combination with cetuximab. HTA ID: 20037](https://www.ncpe.ie/encorafenib-braftovi-in-combination-with-cetuximab-hta-id-20037/)
- [Semaglutide (Rybelsus®). HTA ID: 20011](https://www.ncpe.ie/semaglutide-rybelsus-hta-id-20011/)
- [Formoterol fumarate dihydrate, glycopyrronium, budesonide (Trixeo Aerosphere®). HTA ID: 21015](https://www.ncpe.ie/formoterol-fumarate-dihydrate-glycopyrronium-budesonide-trixeo-aerosphere-hta-id-21015/)
- [Ozanimod (Zeposia®). HTA ID: 20045](https://www.ncpe.ie/ozanimod-zeposia-hta-id-20045/)
- [Dupilumab (Dupixent®) for moderate-to-severe atopic dermatitis in adolescent patients. HTA ID: 19056](https://www.ncpe.ie/dupilumab-dupixent-hta-id-19056/)
- [Etrasimod (Velsipity®). HTA ID: 24012](https://www.ncpe.ie/etrasimod-velsipity-hta-id-24012/)
- [Selpercatinib (Retsevmo®) for advanced RET fusion-positive thyroid cancer. HTA ID: 25034b](https://www.ncpe.ie/selpercatinib-retsevmo-for-advanced-ret-fusion-positive-thyroid-cancer-hta-id-25034b/)
- [Selpercatinib (Retsevmo®) for advanced RET-mutant medullary thyroid cancer. HTA ID: 25034a](https://www.ncpe.ie/selpercatinib-retsevmo-for-advanced-ret-mutant-medullary-thyroid-cancer-hta-id-25034a/)
- [Elranatamab (Elrexfio®). HTA ID: 23066](https://www.ncpe.ie/elranatamab-elrexfio-hta-id-23066/)
- [Omeprazole (Appizped®). HTA ID: 25038](https://www.ncpe.ie/omeprazole-appizped-hta-id-25038/)
- [Nivolumab (Opdivo®) subcutaneous. HTA ID: 25036](https://www.ncpe.ie/nivolumab-opdivo-subcutaneous-hta-id-25036/)
- [Olaparib (Lynparza®) in combination with abiraterone and prednisone. HTA ID: 23029](https://www.ncpe.ie/olaparib-lynparza-in-combination-with-abiraterone-and-prednisone-hta-id-23029/)
- [Tislelizumab (Tevimbra®). HTA ID 25033](https://www.ncpe.ie/tislelizumab-tevimbra-hta-id-25033/)
- [Abiraterone Acetate (Zytiga®) for mCRPC](https://www.ncpe.ie/abiratone-acetate-zytiga/) - NCPE Pharmacoeconomic Evaluation Abiraterone acetate (Zytiga®)
- [Sulthiame (Ospolot®) oral suspension. HTA ID: 25030](https://www.ncpe.ie/sulthiame-ospolot-oral-suspension-hta-id-25030/)
- [Avapritinib (Ayvakyt®). HTA ID: 25031](https://www.ncpe.ie/avapritinib-ayvakyt-hta-id-25031/)
- [Pembrolizumab (Keytruda®). HTA ID: 23056](https://www.ncpe.ie/pembrolizumab-keytruda-hta-id-23056/)
- [Melphalan flufenamide (Pepaxti®). HTA ID: 25028](https://www.ncpe.ie/melphalan-flufenamide-pepaxti-hta-id-25028/)
- [Cipaglucosidase alfa in combination with miglustat (Pombiliti® in combination with Opfolda®). HTA ID 25027](https://www.ncpe.ie/cipaglucosidase-alfa-in-combination-with-miglustat-pombiliti-in-combination-with-opfolda-hta-id-25027/)
- [Semaglutide 2.4 mg (Wegovy®) in adolescent patients. HTA ID: 25025](https://www.ncpe.ie/semaglutide-2-4-mg-wegovy-in-adolescent-patients-hta-id-25025/)
- [Upadacitinib (Rinvoq®) for giant cell arteritis. HTA ID: 25023](https://www.ncpe.ie/upadacitinib-rinvoq-for-giant-cell-arteritis-hta-id-25023/)
- [Serplulimab (Hetronifly®). HTA ID: 25021](https://www.ncpe.ie/serplulimab-hetronifly-hta-id-25021/)
- [Spesolimab (Spevigo®). HTA ID: 24050](https://www.ncpe.ie/spesolimab-spevigo-hta-id-24050/)
- [Acoramidis (Beyonttra®) HTA ID: 25017](https://www.ncpe.ie/acoramidis-beyonttra-hta-id-25017/)
- [Bimekizumab (Bimzelx®). HTA ID: 25019](https://www.ncpe.ie/bimekizumab-bimzelx-hta-id-25019/)
- [Bimekizumab (Bimzelx®). HTA ID: 25018](https://www.ncpe.ie/bimekizumab-bimzelx-hta-id-25018/)
- [Pasireotide LAR (Signifor® LAR). HTA ID: 22034](https://www.ncpe.ie/pasireotide-lar-signifor-lar-hta-id-22034/)
- [Semaglutide (Wegovy®). HTA ID: 22029](https://www.ncpe.ie/semaglutide-wegovy/)
- [Isavuconazole (Cresemba®). HTA ID: 25016](https://www.ncpe.ie/isavuconazole-cresemba-hta-id-25016/)
- [Rucaparib (Rubraca®). HTA ID: 25011](https://www.ncpe.ie/rucaparib-rubraca-hta-id-25011/)
- [Mosunetuzumab (Lunsumio®). HTA ID: 23023](https://www.ncpe.ie/mosunetuzumab-lunsumio-hta-id-23023/)
- [Icosapent ethyl (Vazkepa®). HTA ID: 23006](https://www.ncpe.ie/icosapent-ethyl-vazkepa/)
- [Ocrelizumab subcutaneous (Ocrevus SC®). HTA ID: 25015](https://www.ncpe.ie/ocrelizumab-subcutaneous-ocrevus-sc-hta-id-25015/)
- [Rimegepant (Vydura®). HTA ID: 22051](https://www.ncpe.ie/rimegepant-vydura-hta-id-22051-2/)
- [Ravulizumab (Ultomiris®). HTA ID: 25012](https://www.ncpe.ie/ravulizumab-ultomiris-hta-id-25012/)
- [Macitentan plus tadalafil (Yuvanci®). HTA ID: 25009](https://www.ncpe.ie/macitentan-plus-tadalafil-yuvanci-hta-id-25009/)
- [Artesunate (Artesunate Amivas®). HTA ID: 24019](https://www.ncpe.ie/artesunate-artesunate-amivas-hta-id-24019/)
- [Dantrolene sodium hemiheptahydrate (Agilus®). HTA ID: 24016](https://www.ncpe.ie/dantrolene-sodium-hemiheptahydrate-agilus-hta-id-24016/)
- [Rezafungin (Rezzayo®). HTA ID: 24007](https://www.ncpe.ie/rezafungin-rezzayo-hta-id-24007/)
- [Triumeq® dispersible tablet (DT) (dolutegravir sodium, abacavir sulphate, and lamivudine). HTA ID: 24036](https://www.ncpe.ie/triumeq-dispersible-tablet-dt-dolutegravir-sodium-abacavir-sulphate-and-lamivudine-hta-id-24036/)
- [Rimegepant (Vydura®). HTA ID: 22051](https://www.ncpe.ie/rimegepant-vydura-hta-id-22051/)
- [Nirmatrelvir/Ritonavir (Paxlovid®). HTA ID: 22014](https://www.ncpe.ie/pf-07321332-ritonavir-paxlovid-hta-id-22014/)
- [Quizartinib (Vanflyta®). HTA ID: 24006](https://www.ncpe.ie/quizartinib-vanflyta-hta-id-24006/)
- [Atogepant (Aquipta®). HTA ID: 23039](https://www.ncpe.ie/atogepant-aquipta-hta-id-23039/)
- [Atogepant (Aquipta®) for prophylaxis of episodic migraine. HTA ID: 23059](https://www.ncpe.ie/atogepant-aquipta-for-prophylaxis-of-episodic-migraine-hta-id-23059/)
- [Copper Coil (Yanae® Cu-IUD 380 Mini). HTA ID: 24022](https://www.ncpe.ie/copper-coil-yanae-cu-iud-380-mini-hta-id-24022/)
- [Nivolumab (Opdivo®) for muscle invasive urothelial carcinoma. HTA ID: 22046](https://www.ncpe.ie/nivolumab-opdivo-for-muscle-invasive-urothelial-carcinoma-hta-id-22046/)
- [Pembrolizumab (Keytruda®) for adjuvant treatment of RCC. HTA ID: 22026](https://www.ncpe.ie/pembrolizumab-keytruda-for-adjuvant-treatment-of-rcc-hta-id-22026/)
- [Pembrolizumab (Keytruda®) adjuvant treatment of stage IIB or IIC melanoma. HTA ID: 22042](https://www.ncpe.ie/pembrolizumab-keytruda-adjuvant-treatment-of-stage-iib-or-iic-melanoma-hta-id-22042/)
- [Fostemsavir (Rukobia ®). HTA ID: 23018](https://www.ncpe.ie/fostemsavir-rukobia-hta-id-23018/)
- [Romosozumab (Evenity®). HTA ID: 21016](https://www.ncpe.ie/romosozumab-evenity-hta-id-21016/)
- [Odevixibat (Bylvay®). HTA ID: 21058](https://www.ncpe.ie/odevixibat-bylvay-hta-id-21058/)
- [Lebrikizumab (Ebglyss®). HTA ID: 25008](https://www.ncpe.ie/lebrikizumab-ebglyss-hta-id-25008/)
- [Tebentafusp (Kimmtrak®). HTA ID: 23064](https://www.ncpe.ie/tebentafusp-kimmtrak-hta-id-23064/)
- [European Commission Opens First Request Period for Joint Scientific Consultations](https://www.ncpe.ie/european-commission-opens-first-request-period-for-joint-scientific-consultations/)
- [Mavacamten (Camzyos®). HTA ID: 23028](https://www.ncpe.ie/mavacamten-camzyos-hta-id-23028/)
- [Cemiplimab (Libtayo®). HTA ID: 24048](https://www.ncpe.ie/cemiplimab-libtayo-hta-id-24048/)
- [New European legislation for Health Technology Assessment welcomed by the NCPE](https://www.ncpe.ie/new-european-legislation-for-health-technology-assessment-welcomed-by-the-ncpe/)
- [Christmas arrangements](https://www.ncpe.ie/christmas-arrangements-2/)
- [Eplontersen (Wainzua®) HTA ID: 24047](https://www.ncpe.ie/eplontersen-wainzua-hta-id-24047/)
- [Abrocitinib (Cibinqo®). HTA ID: 21056](https://www.ncpe.ie/abrocitinib-cibinqo-hta-id-21056/)
- [Selumetinib (Koselugo®). HTA ID: 22032](https://www.ncpe.ie/selumetinib-koselugo-hta-id-22032/)
- [Dupilumab (Dupixent®) For severe chronic rhinosinusitis with nasal polyposis. HTA ID: 23046](https://www.ncpe.ie/dupilumab-dupixent-for-severe-chronic-rhinosinusitis-with-nasal-polyposis-hta-id-23046/)
- [Imlifidase (Idefirix®). HTA ID: 23041](https://www.ncpe.ie/imlifidase-idefirix-hta-id-23041/)
- [Vibegron (Obgemsa®) HTA ID: 24043](https://www.ncpe.ie/vibegron-obgemsa-hta-id-24043/)
- [Entrectinib (Rozlytrek®). HTA ID: 22055](https://www.ncpe.ie/e/)
- [Cemiplimab (Libtayo®). HTA ID: 21007](https://www.ncpe.ie/cemiplimab-libtayo-hta-id-21007/)
- [Bempedoic acid/Ezetimibe (Nustendi®). HTA ID: 20026b](https://www.ncpe.ie/bempedoic-acid-ezetimibe-nustendi-hta-id-20026b/)
- [Bempedoic acid (Nilemdo®). HTA ID: 20026a](https://www.ncpe.ie/bempedoic-acid-nilemdo-hta-id-20026a/)
- [Ublituximab (Briumvi®). HTA ID: 24008](https://www.ncpe.ie/ublituximab-briumvi-hta-id-24008/)
- [Momelotinib (Omjjara®). HTA ID: 24002](https://www.ncpe.ie/momelotinib-omjjara-hta-id-24002/)
- [Sacituzumab govitecan (Trodelvy®). HTA ID: 22007](https://www.ncpe.ie/sacituzumab-govitecan-trodelvy-hta-id-22007/)
- [Trastuzumab deruxtecan (Enhertu®). HTA ID: 22050](https://www.ncpe.ie/trastuzumab-deruxtecan-enhertu-hta-id-22050/)
- [Polatuzumab vedotin (Polivy®). HTA ID: 22043](https://www.ncpe.ie/polatuzumab-vedotin-polivy-hta-id-22043/)
- [Tepotinib (Tepmetko®). HTA ID: 22025](https://www.ncpe.ie/tepotinib-tepmetko-hta-id-22025/)
- [Difelikefalin (Kapruvia®). HTA ID: 23001](https://www.ncpe.ie/difelikefalin-kapruvia/)
- [Fondaparinux (Arixtra®). HTA ID: 23019](https://www.ncpe.ie/fondaparinux-arixtra-hta-id-23019/)
- [Chlormethine gel  (Ledaga®). HTA ID: 23049](https://www.ncpe.ie/chlormethine-gel-ledaga-hta-id-23049/)
- [Berotralstat (Orladeyo®). HTA ID: 22031](https://www.ncpe.ie/berotralstat-orladeyo-hta-id-22031/)
- [Dapagliflozin (Forxiga®). HTA ID: 22040](https://www.ncpe.ie/dapagliflozin/)
- [Regorafenib (Stivarga®) for mCRC](https://www.ncpe.ie/rigorafenib-stivarga/) - NCPE Pharmacoeconomic Evaluation Regorafenib (Stivarga®)
- [NCPE Head of Strategy appointed as European HTA Coordination group Chair](https://www.ncpe.ie/ncpe-head-of-strategy-appointed-as-european-hta-coordination-group-chair/)
- [Ropeginterferon alfa-2b (Besremi®). HTA ID: 23004](https://www.ncpe.ie/ropeginterferon-alfa-2b-besremi/)
- [Defatted powder of Arachis hypogaea L., semen (peanuts) (Palforzia®). HTA ID: 22019](https://www.ncpe.ie/defatted-powder-of-arachis-hypogaea-l-semen-peanuts-palforzia-hta-id-22019/)
- [Burosumab (Crysvita®). HTA ID: 23005](https://www.ncpe.ie/burosumab-crysvita-2/)
- [Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®). HTA ID: 23002](https://www.ncpe.ie/lutetium-177lu-vipivotide-tetraxetan-pluvicto/)
- [Ceftaroline (Zinforo®)](https://www.ncpe.ie/ceftaroline-zinforo/) - NCPE Pharmacoeconomic Evaluation Ceftaroline (Zinforo®)
- [Pegvaliase (Palynziq®). HTA ID: 20001](https://www.ncpe.ie/pegvaliase-palynziq-hta-id-20001/)
- [Budesonide (Jorveza®). HTA ID: 24014](https://www.ncpe.ie/budesonide-jorveza-hta-id-24014/)
- [Carfilzomib (Kyprolis®) in combination with daratumumab and dexamethasone (CAR+DAR+DEX). HTA ID: 20054](https://www.ncpe.ie/carfilzomib-kyprolis-in-combination-with-daratumumab-and-dexamethasone-cardardex-hta-id-20054/)
- [Alectinib (Alecensa®). HTA ID: 24017](https://www.ncpe.ie/alectinib-alecensa-hta-id-24017/)
- [Risankizumab (Skyrizi®) for Crohn’s Disease. HTA ID: 23061](https://www.ncpe.ie/risankizumab-skyrizi-for-crohns-disease-hta-id-23061/)
- [Cytisine (Citidaron®). HTA ID: 23063](https://www.ncpe.ie/cytisine-citidaron-hta-id-23063/)
- [Atezolizumab (Tecentriq®) in combination with bevacizumab. HTA ID: 20060](https://www.ncpe.ie/atezolizumab-tecentriq-in-combination-with-bevacizumab-hta-id-20060/)
- [Cefiderocol (Fetcroja®). HTA ID: 22003](https://www.ncpe.ie/cefiderocol-fetcroja-hta-id-22003/)
- [Daratumumab (Darzalex®). HTA ID: 22039](https://www.ncpe.ie/daratumumab/)
- [Pembrolizumab (Keytruda®) for neoadjuvant/adjuvant treatment of triple negative breast cancer. HTA ID: 22027](https://www.ncpe.ie/pembrolizumab-keytruda-for-neoadjuvant-adjuvant-treatment-of-triple-negative-breast-cancer-hta-id-22027/)
- [Daratumumab (Darzalex®). HTA ID: 21041](https://www.ncpe.ie/daratumumab-darzalex-in-combination-with-cyclophosphamide-bortezomib-and-dexamethasone-hta-id-21041/)
- [Avacopan (Tavneos®). HTA ID: 22009](https://www.ncpe.ie/avacopan-tavneos-hta-id-22009/)
- [Venetoclax (Venclyxto®) for Acute Myeloid Leukaemia. HTA ID: 22001](https://www.ncpe.ie/venetoclax-venclyxto-for-acute-myeloid-leukaemia-hta-id-22001/)
- [Vutrisiran (Amvuttra®). HTA ID: 23035](https://www.ncpe.ie/vutrisiran-amvuttra-hta-id-23035/)
- [Abemaciclib (Verzenios®). HTA ID: 22020](https://www.ncpe.ie/abemaciclib-verzenios-for-adjuvant-hr-positive-her2-negative-node-positive-early-breast-cancer-hta-id-22020/)
- [Nivolumab (Opdivo®). HTA ID: 23050](https://www.ncpe.ie/nivolumab-opdivo-hta-id-23050/)
- [Netarsudil-latanoprost (Roclanda®). HTA ID: 23076](https://www.ncpe.ie/netarsudil-latanoprost-roclanda-hta-id-23076/)
- [Buprenorphine prolonged-release solution for injection (Buvidal®). HTA ID: 22056](https://www.ncpe.ie/buprenorphine-prolonged-release-solution-for-injection-buvidal-hta-id-22056/)
- [Bimekizumab (Bimzelx®) for psoriatic arthritis. HTA ID: 23075](https://www.ncpe.ie/bimekizumab-bimzelx-for-psoriatic-arthritis-hta-id-23075/)
- [Cannabidiol (Epidyolex®). HTA ID: 21024](https://www.ncpe.ie/cannabidiol-epidyolex-for-the-treatment-of-tuberous-sclerosis-complex-hta-id-21024/)
- [Cannabidiol (Epidyolex®). HTA ID: 20005](https://www.ncpe.ie/cannabidiol-epidyolex-for-the-treatment-of-lennox-gastaut-syndrome-hta-id-20005/)
- [Cannabidiol (Epidyolex®). HTA ID: 20004](https://www.ncpe.ie/cannabidiol-epidyolex-for-the-treatment-of-dravet-syndrome-hta-id-20004/)
- [Atezolizumab (Tecentriq®) for adjuvant treatment of NSCLC. HTA ID: 22036](https://www.ncpe.ie/atezolizumab-tecentriq-for-adjuvant-treatment-of-nsclc-hta-id-22036/)
- [Meningitis B Vaccine – February 2014](https://www.ncpe.ie/meningitis-b-vaccine-february-2014/)
- [Baricitinib (Olumiant®) for moderate to severe active rheumatoid arthritis](https://www.ncpe.ie/baricitinib-olumiant/) - NCPE Pharmacoeconomic Evaluation Baricitinib (Olumiant®)
- [Enzalutamide (Xtandi®) on or after chemotherapy](https://www.ncpe.ie/enzalutamide-xtandi/) - NCPE Pharmacoeconomic Evaluation Enzalutamide (Xtandi®)
- [Lumacaftor/ivacaftor (Orkambi®)](https://www.ncpe.ie/lumacaftorivacaftor-orkambi/) - NCPE Pharmacoeconomic Evaluation Lumacaftor/ivacaftor (Orkambi®)
- [Osimertinib (Tagrisso®) Adjuvant treatment stage IB-IIIA NSCLC. HTA ID: 21066](https://www.ncpe.ie/osimertinib-tagrisso-adjuvant-treatment-stage-ib-iiia-nsclc-hta-id-21066/)
- [Maribavir (Livtencity®). HTA ID: 22069](https://www.ncpe.ie/maribavir-livtencity-hta-id-22069/)
- [Foslevodopa/foscarbidopa (Produodopa®). HTA ID: 23007](https://www.ncpe.ie/foslevodopa-foscarbidopa-produodopa-hta-id-23007/)
- [Doxylamine/pyridoxine (Cariban®). HTA ID: 23052](https://www.ncpe.ie/doxylamine-pyridoxine-cariban-hta-id-23052/)
- [Relugolix (Orgovyx®). HTA ID: 23017](https://www.ncpe.ie/relugolix-orgovyx-hta-id-23017/)
- [Deucravacitinib (Sotyktu®). HTA ID: 23030](https://www.ncpe.ie/deucravacitinib-sotyktu-hta-id-23030/)
- [Dapagliflozin (Forxiga®). HTA ID: 23065](https://www.ncpe.ie/dapagliflozin-forxiga-hta-id-23065/)
- [Enfortumab vedotin (Padcev®). HTA ID: 22024](https://www.ncpe.ie/enfortumab-vedotin-padcev-hta-id-22024/)
- [Oral Azacitidine (Onureg®). HTA ID: 22070](https://www.ncpe.ie/oral-azacitidine-onureg/)
- [Dupilumab (Dupixent®) for severe asthma. HTA ID: 21063](https://www.ncpe.ie/dupilumab-dupixent-for-severe-asthma-hta-id-21063/)
- [Dapagliflozin (Forxiga®). HTA ID: 22030](https://www.ncpe.ie/dapagliflozin-forxiga-hta-id-22030/)
- [Acalabrutinib (Calquence®). HTA ID: 23012](https://www.ncpe.ie/acalabrutinib-calquence-hta-id-23012/)
- [Statement from the Heads of HTA Agency on the Pharmaceutical Legislation](https://www.ncpe.ie/updated-statement-from-the-heads-of-hta-agency-on-the-pharmaceutical-legislation/)
- [Capmatinib (Tabrecta®). HTA ID: 22049](https://www.ncpe.ie/capmatinib-tabrecta-hta-id-22049/)
- [Upadacitinib (Rinvoq®). HTA ID: 23013](https://www.ncpe.ie/upadacitinib-rinvoq-hta-id-23013/)
- [Ibrutinib (Imbruvica®). HTA ID: 22054](https://www.ncpe.ie/ibrutinib-imbruvica-hta-id-22054/)
- [Atidarsagene (Libmeldy®). HTA ID: 21009](https://www.ncpe.ie/atidarsagene-libmeldy/)
- [Finerenone (Kerendia®). HTA ID: 23077](https://www.ncpe.ie/finerenone-kerendia-hta-id-23077/)
- [Sufentanil Citrate (Dzuveo®) HTA ID: 23062](https://www.ncpe.ie/sufentanil-citrate-dzuveo-hta-id-23062/)
- [Talazoparib (Talzenna®) in combination with enzalutamide for mCRPC. HTA ID: 23074](https://www.ncpe.ie/talazoparib-talzenna-in-combination-with-enzalutamide-for-mcrpc-hta-id-23074/)
- [Pembrolizumab (Keytruda®) in combination with lenvatinib (Lenvima®) for endometrial carcinoma. HTA ID: 22006](https://www.ncpe.ie/pembrolizumab-keytruda-in-combination-with-lenvatinib-lenvima-for-endometrial-carcinoma-hta-id-22006/)
- [Melphalan flufenamide (Pepaxti®). HTA ID: 23067](https://www.ncpe.ie/melphalan-flufenamide-pepaxti-hta-id-23067/)
- [Somapacitan (Sogroya®). HTA ID: 23060](https://www.ncpe.ie/somapacitan-sogroya-hta-id-23060/)
- [Pitolisant hydrochloride (Wakix®) for the treatment of narcolepsy with or without cataplexy in adolescents and children aged 6 years and older. HTA ID: 23054](https://www.ncpe.ie/pitolisant-hydrochloride-wakix-for-the-treatment-of-narcolepsy-with-or-without-cataplexy-in-adolescents-and-children-aged-6-years-and-older-hta-id-23054/)
- [Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex®)](https://www.ncpe.ie/delta-9-tetrahydrocannabinol-cannabidiol-thc-cbd-sativex/) - NCPE Pharmacoeconomic Evaluation Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex®)
- [Niraparib in combination with abiraterone acetate (Akeega®). HTA ID: 23032](https://www.ncpe.ie/niraparib-in-combination-with-abiraterone-acetate-akeega-hta-id-23032/)
- [Asciminib (Scemblix®). HTA ID: 22053](https://www.ncpe.ie/asciminib-scemblix-hta-22053/)
- [Amikacin Sulfate (Arikayce® liposomal nebuliser dispersion). HTA ID: 20048](https://www.ncpe.ie/amikacin-sulfate-arikayce-liposomal-nuebuliser-dispersion-hta-id-20048/)
- [Pegunigalsidase alfa (Elfabrio®). HTA ID: 23020](https://www.ncpe.ie/pegunigalsidase-alfa-elfabrio-hta-id-23020/)
- [Zanubrutinib (Brukinsa®). HTA ID: 23010](https://www.ncpe.ie/zanubrutinib-brukinsa-hta-id-23010/)
- [Empaglifozin (Jardiance®). HTA ID: 22068](https://www.ncpe.ie/13280-2/)
- [Nivolumab (Opdivo®) for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer. HTA ID: 21043](https://www.ncpe.ie/nivolumab-opdivo-for-adjuvant-treatment-of-oesophageal-or-gastro-oesophageal-junction-cancer-hta-id-21043/)
- [Olaparib (Lynparza®) in combination with bevacizumab (1L maintenance HRD positive ovarian cancer). HTA ID: 21011](https://www.ncpe.ie/olaparib-lynparza-in-combination-with-bevacizumab-1l-maintenance-hrd-positive-ovarian-cancer-hta-id-21011/)
- [Risdiplam (Evrysdi™). HTA ID: 21006](https://www.ncpe.ie/risdiplam-evrysdi-hta-id-21006/)
- [Voretigene neparvovec (Luxturna®). HTA ID: 19041](https://www.ncpe.ie/voretigene-neparvovec-luxturna/)
- [Macimorelin acetate (Ghryvelin®). HTA ID: 22062](https://www.ncpe.ie/macimorelin-acetate-ghryvelin-hta-id-22062/)
- [Nivolumab (Opdivo®) for unresectable, advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) 1L. HTA ID: 22045](https://www.ncpe.ie/nivolumab-opdivofor-unresectable-advanced-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma-oscc-1l/)
- [Eptinezumab (Vyepti®). HTA ID: 22052](https://www.ncpe.ie/e-2/)
- [Eladocagene exuparvovec. HTA ID: 22072](https://www.ncpe.ie/eladocagene-exuparvovec/)
- [Tixagevimab /cilgavimab (Evusheld®). HTA ID: 22015](https://www.ncpe.ie/tixagevimab-cilgavimab-evusheld-hta-id-22015/)
- [Empagliflozin (Jardiance®). HTA ID: 21030](https://www.ncpe.ie/empagliflozin-jardiance-hta-id-21030/)
- [Vericiguat (Verquvo®). HTA ID: 21027](https://www.ncpe.ie/vericiguat-verquvo-hta-id-21027/)
- [Cenobamate (Ontozry®). HTA ID: 21025](https://www.ncpe.ie/cenobamate-ontozry-hta-id-21025/)
- [Nivolumab in combination with ipilimumab (Opdivo® and Yervoy®) malignant pleural mesothelioma. HTA ID: 21018](https://www.ncpe.ie/nivolumab-in-combination-with-ipilimumab-opdivo-and-yervoy-malignant-pleural-mesothelioma-hta-id-21018/)
- [Niraparib (Zejula®) for 1L maintenance OVCA. HTA ID: 21004](https://www.ncpe.ie/niraparib-zejula-1l-maintenance-ovca-hta-id-21004/)
- [Pembrolizumab (Keytruda®) for colorectal cancer. HTA ID: 21002](https://www.ncpe.ie/pembrolizumab-keytruda-for-colorectal-cancer-hta-id-21002/)
- [Vosoritide (Voxzogo®). HTA ID: 22028](https://www.ncpe.ie/vosoritide-voxzogo-hta-id-22028/)
- [Glofitamab (Columvi®). HTA ID: 23055](https://www.ncpe.ie/glofitamab-columvi-hta-id-23055/)
- [Pertuzumab (Perjeta®)](https://www.ncpe.ie/pertuzumab-perjeta/) - NCPE Pertuzumab (Perjeta®) Assessment
- [Pembrolizumab (Keytruda®) for oesphageal carcinoma or HER-2 negative gastroesophageal junction adenocarcinoma. HTA ID: 21032](https://www.ncpe.ie/pembrolizumab-keytruda-hta-id-21032/)
- [Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) (Colorectal cancer). HTA ID: 21023](https://www.ncpe.ie/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy-colorectal-cancer-hta-id-21023/)
- [Mogamulizumab (Poteligeo®). HTA ID: 20061](https://www.ncpe.ie/mogamulizumab-poteligeo-hta-id-20061/)
- [House Dust Mite Extract (Acarizax ®) for Allergic Asthma. HTA ID: 20016](https://www.ncpe.ie/house-dust-mite-extract-acarizax-for-allergic-asthma-hta-id-20016/)
- [Dupilumab (Dupixent®) for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.](https://www.ncpe.ie/dupilumab-dupixent/) - NCPE Pharmacoeconomic Evaluation Dupilumab (Dupixent®)
- [Dupilumab (Dupixent®) for eosinophilic oesophagitis. HTA ID: 23047](https://www.ncpe.ie/dupilumab-dupixent-for-eosinophilic-oesophagitis-hta-id-23047/)
- [Loncastuximab tesirine (Zynlonta®). HTA ID: 23053](https://www.ncpe.ie/loncastuximab-tesirine-zynlonta-hta-id-23053/)
- [Finerenone (Kerendia®). HTA ID: 22012](https://www.ncpe.ie/finerenone-kerendia-hta-id-22012/)
- [Absolute risk](https://www.ncpe.ie/absolute-risk/) - NCPE Glossary Absolute risk
- [Galcanezumab (Emgality®). HTA ID: 20052](https://www.ncpe.ie/galcanezumab-emgality-hta-id-20052/)
- [Argipressin acetate (Embesin®)](https://www.ncpe.ie/argipressin-acetate-embesin/)
- [Beclometasone /formoterol (Fostair®) for COPD. HTA ID 23037](https://www.ncpe.ie/beclometasone-formoterol-fostair-for-copd-hta-id-23037/)
- [Beclometasone/formoterol (Fostair®) for asthma. HTA ID: 23038](https://www.ncpe.ie/beclometasone-formoterol-fostair-for-asthma-hta-id-23038/)
- [Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®). HTA ID: 23033](https://www.ncpe.ie/beclometasone-dipropionate-anhydrous-formoterol-fumarate-dihydrate-glycopyrronium-bromide-trimbow-hta-id-23033/)
- [Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®). HTA ID: 23034](https://www.ncpe.ie/beclometasone-dipropionate-anhydrous-formoterol-fumarate-dihydrate-glycopyrronium-bromide-trimbow-hta-id-23034/)
- [Itopride Hydrochloride (Progit®) 23031](https://www.ncpe.ie/itopride-hydrochloride-progit-23031/)
- [Drospirenone/estetrol monohydrate (Drovelis®). HTA ID: 22073](https://www.ncpe.ie/drospirenone-estetrol-monohydrate-drovelis/)
- [Bimekizumab (Bimzelx®). HTA ID: 21052](https://www.ncpe.ie/bimekizumab-bimzelx-hta-id-21052/)
- [Belimumab (Benlysta®) for systemic lupus erythematosus. HTA ID: 23022](https://www.ncpe.ie/belimumab-benlysta-for-systemic-lupus-erythematosus-hta-id-23022/)
- [Burosumab (Crysvita®)](https://www.ncpe.ie/burosumab-crysvita/)
- [Buprenorphine/Naloxone (Suboxone®)](https://www.ncpe.ie/suboxone-buprenorphinenaloxone/) - NCPE Pharmacoeconomic Evaluation Suboxone® (buprenorphine/naloxone)
- [Brentuximab vedotin (Adcetris®) for CD30+ Hodgkins lymphoma. HTA ID: 19058](https://www.ncpe.ie/brentuximab-vedotin-adcetris-for-cd30-hodgkins-lymphoma-hta-id-19058/)
- [Brentuximab vedotin (Adcetris®)](https://www.ncpe.ie/brentuximab-vedotin-adcetris/) - NCPE Pharmacoeconomic Evaluation Brentuximab vedotin (Adcetris®)
- [Boceprevir (Victrelis®)](https://www.ncpe.ie/boceprevir-victrelis/) - The NCPE consider boceprevir a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting.
- [Blinatumomab (Blincyto®)](https://www.ncpe.ie/blinatumomab-blincyto/) - NCPE Pharmacoeconomic Evaluation Blinatumomab (Blincyto®)
- [Bendamustine (Levact®)](https://www.ncpe.ie/bendamustine-levact/) - NCPE Pharmacoeconomic Evaluation Bendamustine (Levact®)
- [Axicabtagene Ciloleucel (Yescarta®)](https://www.ncpe.ie/axicabtagene-ciloleucel-yescarta/)
- [Avelumab (Bavencio®). HTA ID: 21001](https://www.ncpe.ie/avelumab-bavencio-1l-maintenance-urothelial-carcinoma-hta-id-21001/)
- [Avelumab (Bavencio®). HTA ID: 19046](https://www.ncpe.ie/avelumab-bavencio-in-combination-with-axitinib-inlyta-for-first-line-treatment-of-metastatic-renal-cell-carcinoma-hta-id-19046/)
- [Avelumab (Bavencio®)](https://www.ncpe.ie/avelumab-bavencio/) - NCPE Pharmacoeconomic Evaluation Avelumab (Bavencio®)
- [Atezolizumab (Tecentriq®) HTA ID: 19030](https://www.ncpe.ie/atezolizumab-tecentriq-in-combination-with-carboplatin-and-etoposide-for-1l-es-sclc/) - NCPE Pharmacoeconomic Evaluation Atezolizumab (Tecentriq®)
- [Atezolizumab (Tecentriq®) for triple-negative breast cancer.](https://www.ncpe.ie/atezolizumab-tecentriq-for-triple-negative-breast-cancer/)
- [Atezolizumab (Tecentriq®)](https://www.ncpe.ie/atezolizumab-tecentriq/) - NCPE Pharmacoeconomic Evaluation Atezolizumab
- [Ataluren (Translarna®)](https://www.ncpe.ie/ataluren-translarna-2/)
- [Apremilast (Otezla®)](https://www.ncpe.ie/apremilast-otezla-for-psoriatic-arthritis/) - Pharmacoeconomic Evaluation of Apremilast (Otezla®)
- [Apremilast (Otezla®)](https://www.ncpe.ie/apremilast-otezla-for-moderate-to-severe-chronic-plaque-psoriasis/) - Pharmacoeconomic Evaluation of Apremilast (Otezla®)
- [Apixaban (Eliquis®) for NVAF](https://www.ncpe.ie/apixaban-eliquisfor-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-non-valvular-atrial-fibrillation/)
- [Apixaban (Eliquis®)](https://www.ncpe.ie/apixaban-eliquis/) - NCPE Pharmacoeconomic Evaluation Apixaban (Eliquis®)
- [Apalutamide (Erleada®). HTA ID: 20010](https://www.ncpe.ie/apaluatmide-erleada-hta-id-20010/)
- [Apalutamide (Erleada®) for nmCRPC](https://www.ncpe.ie/apalutamide-erleada-for-nmcrpc/)
- [Andexanet alfa (Ondexxya®). HTA ID: 20014](https://www.ncpe.ie/andexanet-alfa-ondexxya-hta-id-20014/)
- [Amivantamab (Rybrevant®). HTA ID: 22004](https://www.ncpe.ie/amivantamab-rybrevant-hta-id-22004/)
- [Alpelisib (Piqray®). HTA ID: 20035](https://www.ncpe.ie/alpelisib-piqray-hta-id-20035/)
- [Alirocumab (Praluent®)](https://www.ncpe.ie/alirocumab-praluent/) - NCPE Pharmacoeconomic Evaluation NCPE Alirocumab (Praluent®) Assessment
- [Alemtuzumab (Lemtrada®)](https://www.ncpe.ie/alemtuzumab-lemtrada/) - NCPE Pharmacoeconomic Evaluation Alemtuzumab (Lemtrada®)
- [Alectinib (Alecensa®) for the 1L treatment of ALK+ advanced NSCLC](https://www.ncpe.ie/alectinib-alecensa-2/)
- [Agomelatine (Valdoxan®)](https://www.ncpe.ie/agomelatine-valdoxan-4/) - NCPE Pharmacoeconomic Evaluation Agomelatine (Valdoxan®)
- [Aflibercept (Zaltrap®)](https://www.ncpe.ie/aflibercept-zaltrap/) - NCPE Pharmacoeconomic Evaluation Aflibercept (Zaltrap®)
- [Abiraterone acetate (Zytiga®) for mCRPC post ADT](https://www.ncpe.ie/abiratone-acetate-zytiga-for-mcrpc-post-adt/) - NCPE Pharmacoeconomic Evaluation Abiratone acetate (Zytiga®)
- [Abatacept (Orencia®)](https://www.ncpe.ie/abatacept-orencia/) - NCPE Pharmacoeconomic Evaluation Abatacept (Orencia®)
- [Durvalumab (Imfinzi®)](https://www.ncpe.ie/durvalumab-imfinzi/) - NCPE Pharmacoeconomic Evaluation Durvalumab (Imfinzi®)
- [Dostarlimab (Jemperli®). HTA ID: 21045](https://www.ncpe.ie/dostarlimab-jemperli-hta-id-21045/)
- [Dinutuximab beta (Qarziba®)](https://www.ncpe.ie/dinutuximab-beta-dinutuximab-beta-eusa/) - NCPE Pharmacoeconomic Evaluation Dinutuximab beta (Dinutuximab beta EUSA®)
- [Dimethyl fumarate (Tecfidera®)](https://www.ncpe.ie/dimethyl-fumarate-tecfidera/) - NCPE Pharmacoeconomic Evaluation Dimethyl fumarate (Tecfidera®)
- [Dexamethasone Intravitreal Implant (Ozurdex®)](https://www.ncpe.ie/dexamethasone-intravitreal-implant-ozurdex/) - NCPE Pharmacoeconomic Evaluation Dexamethasone Intravitreal Implant (Ozurdex®
- [Denosumab (Xgeva®)](https://www.ncpe.ie/denosumab-xgeva-3/) - The NCPE consider denosumab (XGEVA®) a cost-effective therapy for the prevention of skeletal-related events in adults with bone metastases from solid tumours in the Irish healthcare setting.
- [Denosumab (Prolia®)](https://www.ncpe.ie/denosumab-prolia/) - The NCPE consider Denosumab (Prolia®) a cost-effective therapy for the prevention of osteoporotic fractures in postmenopausal women in the Irish healthcare setting.
- [Darvadstrocel (Alofisel®)](https://www.ncpe.ie/darvadstrocel-alofisel/)
- [Darolutamide (Nubeqa®). HTA ID: 20022](https://www.ncpe.ie/darolutamide-nubeqa-hta-id-20022/)
- [Daratumumab (Darzalex®). HTA ID: 20025](https://www.ncpe.ie/daratumamab-darzalex-hta-id-20025/)
- [Daratumumab (Darzalex®) in combination with bortezomib and dexamethasone](https://www.ncpe.ie/daratumumab-darzalex-combination-therapy/) - NCPE Pharmacoeconomic Evaluation of Daratumumab (Darzalex®) for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
- [Daratumumab (Darzalex®)](https://www.ncpe.ie/daratumumab-darzalex/) - Pharmacoeconomic evaluation of daratumumab (Darzalex®) monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
- [Daclatasvir (Daklinza®)](https://www.ncpe.ie/daclatasvir-daklinza/)
- [Dabrafenib plus Trametinib (Tafinlar® plus Mekinist®)](https://www.ncpe.ie/dabrafenib-plus-trametinib-tafinlar-plus-mekinist/)
- [Dabrafenib (Tafinlar®)](https://www.ncpe.ie/dabrafenib-tafinlar/) - NCPE Pharmacoeconomic Evaluation Dabrafenib (Tafinlar®)
- [Dabigatran Etexilate (Pradaxa®) for the treatment of DVT and PE](https://www.ncpe.ie/dabigatran-etexilate-pradaxa-2/)
- [Dabigatran Etexilate (Pradaxa®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement](https://www.ncpe.ie/dabigatran-etexilate-pradaxa-vte-prevention/) - NCPE Pharmacoeconomic Evaluation Dabigatran Etexilate (Pradaxa®)
- [Dabigatran etexilate (Pradaxa®) - for the prevention of stroke and systematic embolisom in atrial fibrillation](https://www.ncpe.ie/dabigatran-etexilate-pradaxa-for-the-prevention-of-stroke-and-systematic-embolisom-in-atrial-fibrillation/)
- [Cysteamine bitartrate delayed-release (Procysbi®)](https://www.ncpe.ie/cysteamine-bitartrate-procysbi/) - NCPE Pharmacoeconomic Evaluation Cysteamine bitartrate (Procysbi®)
- [Crizotinib (Xalkori®)](https://www.ncpe.ie/crizotinib-xalkori/) - NCPE Pharmacoeconomic Evaluation Crizotinib (Xalkori®)
- [Cobimetinib (Cotellic®)](https://www.ncpe.ie/cobimetinib-cotellic/) - NCPE Pharmacoeconomic Evaluation Cobimetinib (Cotellic®)
- [Cladribine (Mavenclad®)](https://www.ncpe.ie/cladribine-mavenclad/)
- [Certolizumab pegol (Cimzia®)](https://www.ncpe.ie/certolizumab-pegol-cimzia/) - The NCPE do not consider Certolizumab cost-effective at the submitted price in September 2010.
- [Cerliponase alfa (Brineura®)](https://www.ncpe.ie/cerliponase-alfa-brineura/) - NCPE Pharmacoeconomic Evaluation Cerliponase alfa (Brineura®)
- [Carfilzomib (Kyprolis®) in combination with lenalidomide and dexamethasone (CAR+LEN+DEX)](https://www.ncpe.ie/carfilzomib-kyprolis/) - NCPE Pharmacoeconomic Evaluation Carfilzomib (Kyprolis®)
- [Canagliflozin (Invokana®)](https://www.ncpe.ie/canagliflozin-invokana/) - NCPE Pharmacoeconomic Evaluation Canagliflozin (Invokana®)
- [Cabazitaxel (Jevtana®)](https://www.ncpe.ie/carbazitaxel-jevtana-for-prostate-cancer/) - NCPE Pharmacoeconomic Evaluation Carbazitaxel (Jevtana®)
- [Cabozantinib (Cabometyx®)](https://www.ncpe.ie/cabozantinib-cabometyx/) - NCPE Pharmacoeconomic Evaluation Cabozantinib (Cabometyx ®)
- [Belimumab (Benlysta®) for lupus nephritis. HTA ID: 23021](https://www.ncpe.ie/belimumab-benlysta-for-lupus-nephritis-hta-id-23021/)
- [Patiromer (Veltassa®)](https://www.ncpe.ie/patiromer-veltassa/) - NCPE Pharmacoeconomic Evaluation Patiromer (Veltassa®)
- [Olaparib (Lynparza®) for mCRPC. HTA ID: 21019](https://www.ncpe.ie/olaparib-lynparza-for-mcrpc-hta-id-21019/)
- [Cholecalciferol (Egostar®). HTA ID: 22033](https://www.ncpe.ie/cholecalciferol-egostar-hta-id-22033/)
- [Liraglutide (Saxenda®). HTA ID: 19039](https://www.ncpe.ie/liraglutide-saxenda/)
- [Eribulin (Halaven®)](https://www.ncpe.ie/eribulin-halaven/) - NCPE Pharmacoeconomic Evaluation Eribulin (Halaven®)
- [Pembrolizumab (Keytruda®) for persistent, recurrent or metastatic cervical cancer. HTA ID: 22041](https://www.ncpe.ie/pembrolizumab-keytruda-for-persistent-recurrent-or-metastatic-cervical-cancer-hta-id-22041/)
- [Somatrogon (Ngenla®). HTA ID: 22010](https://www.ncpe.ie/somatrogon-ngenla-hta-id-22010/)
- [Lorlatinib (Lorviqua®) for 1L ALK positive NSCLC. HTA ID: 21071](https://www.ncpe.ie/lorlatinib-lorviqua-for-1l-alk-positive-nsclc-hta-id-21071/)
- [Solriamfetol (Sunosi®). HTA ID: 22017](https://www.ncpe.ie/solriamfetol-sunosi-hta-id-22017/)
- [Diroximel fumarate (Vumerity®). HTA ID: 21047](https://www.ncpe.ie/diroximel-fumarate-vumerity-hta-id-21047/)
- [Oritavancin (Tenkasi®). HTA ID: 21061](https://www.ncpe.ie/oritavancin-tenkasi-hta-id-21061/)
- [Entrectinib (Rozlytrek®) for ROS1-positive advanced NSCLC. HTA ID: 21038](https://www.ncpe.ie/entrectinib-rozlytrek-for-ros1-positive-advanced-nsclc-hta-id-21038/)
- [Blinatumomab (Blincyto®). HTA ID: 21031](https://www.ncpe.ie/blinatumomab-blincyto-hta-id-21031/)
- [Mometasone furoate plus olopatadine (Ryaltris®). HTA ID: 21051](https://www.ncpe.ie/mometasone-furoate-plus-olopatadine-ryaltris-hta-id-21051/)
- [Dupilumab (Dupixent®) for severe atopic dermatitis in children 6 to 11 years old. HTA ID: 21035](https://www.ncpe.ie/dupilumab-dupixent-for-severe-atopic-dermatitis-in-children-6-to-11-years-old-hta-id-21035/)
- [Latanoprost/Timolol (Fixapost®). HTA ID: 21053](https://www.ncpe.ie/latanoprost-timolol-fixapost-hta-id-21053/)
- [Vedolizumab (Entyvio®). HTA ID: 20030](https://www.ncpe.ie/vedolizumab-entyvio-hta-id-20030/) - NCPE Pharmacoeconomic Evaluation Vedolizumab (Entyvio®)
- [Vedolizumab (Entyvio®). HTA ID: 20029](https://www.ncpe.ie/vedolizumab-entyvio-hta-id-20029/) - NCPE Pharmacoeconomic Evaluation Vedolizumab (Entyvio®)
- [Ustekinumab (Stelara®) for Ulcerative colitis. HTA ID: 19048](https://www.ncpe.ie/ustekinumab-stelara-for-ulcerative-colitis-hta-id-19048/) - NCPE Pharmacoeconomic Evaluation Ustekinumab (Stelara®)
- [Upadacitinib (Rinvoq®) for psoriatic arthritis. HTA ID: 21040](https://www.ncpe.ie/upadacitinib-rinvoq-for-psoriatic-arthritis-hta-id-21040/)
- [Upadacitinib (Rinvoq®) for atopic dermatitis. HTA ID: 21029](https://www.ncpe.ie/upadacitinib-rinvoq-for-atopic-dermatitis-hta-id-21029/)
- [Upadacitinib (Rinvoq®) for ankylosing spondylitis. HTA ID: 21039](https://www.ncpe.ie/upadacitinib-rinvoq-for-ankylosing-spondylitis-hta-id-21039/)
- [Upadacitinib (Rinvoq®). HTA ID: 22047](https://www.ncpe.ie/u/)
- [Upadacitinib (Rinvoq®). HTA ID: 19047](https://www.ncpe.ie/upadacitinib-rinvoq-hta-id-19047/)
- [Sotorasib (Lumykras™). HTA ID: 21070](https://www.ncpe.ie/sotorasib-lumykras-hta-id-21070/)
- [Sodium hydrogen carbonate (Thamicarb®). HTA ID: 20043](https://www.ncpe.ie/sodium-hydrogen-carbonate-thamicarb-hta-id-20043/)
- [Siponimod (Mayzent®). HTA ID: 19053](https://www.ncpe.ie/siponimod-mayzent-hta-id-19053/) - NCPE Pharmacoeconomic Evaluation Siponimod (Mayzent®)
- [Ruxolitinib (Jakavi®) for Polycythaemia Vera. HTA ID: 20008](https://www.ncpe.ie/ruxolitinib-jakavi-for-polycythaemia-vera/) - NCPE Pharmacoeconomic Evaluation Ruxolitinib (Jakavi®)
- [Roxadustat (Evrenzo™). HTA ID: 21037](https://www.ncpe.ie/roxadustat-evrenzo-hta-id-21037/)
- [Risankizumab (Skyrizi®) for psoriatic arthritis. HTA ID: 22038](https://www.ncpe.ie/risankizumab-skyrizi-for-psoriatic-arthritis-hta-id-22038/)
- [Risankizumab (Skyrizi®). HTA ID: 19010](https://www.ncpe.ie/risankizumab-skyrizi/)
- [Relugolix with estradiol and norethisterone acetate (Ryeqo®). HTA ID: 21055](https://www.ncpe.ie/relugolix-with-estradiol-and-norethisterone-acetate-ryeqo-hta-id-21055/)
- [Regdanvimab (RegkironaTM). HTA ID: 21065](https://www.ncpe.ie/regdanvimab-regkironatm-hta-id-21065/)
- [Ponesimod (Ponvory®). HTA ID: 21036](https://www.ncpe.ie/ponesimod-ponvory-hta-id-21036/)
- [Pomalidomide (Imnovid®) in combination with bortezomib and dexamethasone. HTA ID: 22016](https://www.ncpe.ie/pomalidomide-imnovid-in-combination-with-bortezomib-and-dexamethasone-hta-id-22016/)
- [Polatuzumab vedotin (Polivy®). HTA ID: 19052](https://www.ncpe.ie/polatuzumab-vedotin-polivy-hta-id-19052/) - Rapid Review
- [Pertuzumab and trastuzumab (Phesgo®). HTA ID: 20053](https://www.ncpe.ie/pertuzumab-and-trastuzumab-phesgo-hta-id-20053/)
- [Pembrolizumab (Keytruda®) in combination with axitinib (Inlyta®) for 1L RCC. HTA ID: 19027](https://www.ncpe.ie/pembrolizumab-keytruda-in-combination-with-axitinib-inlyta-for-1l-rcc/)
- [Pembrolizumab (Keytruda®) for metastatic triple negative breast cancer. HTA ID: 21059](https://www.ncpe.ie/pembrolizumab-keytruda-hta-id-21059/)
- [Pembrolizumab (Keytruda®) for head and neck squamous cell carcinoma. HTA ID: 19051](https://www.ncpe.ie/pembrolizumab-keytruda-for-head-and-neck-squamous-cell-carcinoma-hta-id-19051/)
- [Zanubrutinib (Brukinsa®). HTA ID: 21044](https://www.ncpe.ie/zanubrutinib-brukinsa-hta-id-21044/)
- [Pembrolizumab (Keytruda®) for classical Hodgkin Lymphoma. HTA ID: 21013](https://www.ncpe.ie/pembrolizumab-keytruda-for-classical-hodgkin-lymphoma-htaid-21013/) - Pembrolizumab (Keytruda) for classical Hodgkin Lymphoma. NCPE Assessment
- [Pegylated liposomal irinotecan (Onivyde®). HTA ID: 20028](https://www.ncpe.ie/liposomal-irinotecan-nal-iri-onivyde/) - NCPE Pharmacoeconomic Evaluation Liposomal irinotecan (Onivyde®)
- [Ozanimod (Zeposia®) for Ulcerative Colitis. HTA ID: 22002](https://www.ncpe.ie/ozanimod-zeposia-for-ulcerative-colitis-hta-id-22002/)
- [Omeprazole (Pedippi®) 2mg/ml powder for oral suspension. HTA ID: 20049](https://www.ncpe.ie/omeprazole-pedippi-2mg-ml-powder-for-oral-suspension-hta-id-20049-2/) - NCPE Pharmacoeconomic Evaluation Omeprazole (Pedippi®)
- [Nusinersen (Spinraza®). HTA ID: 20044](https://www.ncpe.ie/nusinersen-spinraza-hta-id-20044/)
- [Nivolumab plus Ipilimumab plus platinum-doublet chemotherapy (Opdivo® plus Yervoy®). HTA ID: 21014](https://www.ncpe.ie/nivolumab-plus-ipilimumab-plus-platinum-doublet-chemotherapy-opdivo-plus-yervoy-1l-nsclc-hta-id-21014/)
- [Nivolumab (Opdivo®) As monotherapy for unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (2L). HTA ID: 20057](https://www.ncpe.ie/nivolumab-opdivo-as-monotherapy-for-unresectable-advanced-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma-2l-hta-id-20057/)
- [Nintedanib (Ofev®). HTA ID: 20034](https://www.ncpe.ie/nintedanib-ofev-hta-id-20034/)
- [Neratinib (Nerlynx®). HTA ID: 19057](https://www.ncpe.ie/neratinib-nerlynx-hta-id-19057/)
- [Naloxone (Nyxoid®) intranasal spray. HTA ID: 20019](https://www.ncpe.ie/naloxone-nyxoid-intranasal-spray-hta-id-20019/)
- [Molnupiravir (Lagevrio®). HTA ID: 21060](https://www.ncpe.ie/molnupiravir-lagevrio-hta-id-21060/)
- [Methyl aminolevulinate (Metvix®). HTA ID: 19049](https://www.ncpe.ie/methyl-aminolevulinate-metvix-hta-id-19049/)
- [Meropenem/vaborbactam (Vaborem®). HTA ID: 20007](https://www.ncpe.ie/meropenem-vaborbactam-vaborem-hta-id-20007/)
- [Levodopa/carbidopa/entacapone intestinal gel (Lecigon®). HTA ID: 21068](https://www.ncpe.ie/levodopa-carbidopa-entacapone-intestinal-gel-lecigon-hta-id-21068/)
- [Indacterol/mometasone furoate (Atectura®). HTA ID: 20024](https://www.ncpe.ie/indacterol-mometasone-furoate-atectura-hta-id-20024/)
- [Ibrutinib (Imbruvica®). HTA ID: 20032](https://www.ncpe.ie/ibrutinib-imbruvica-2/)
- [Guselkumab (Tremfya®) for psoriatic arthritis. HTA ID: 20059](https://www.ncpe.ie/guselkumab-tremfya-for-psoriatic-arthritis-hta-id-20059/)
- [Filgotinib (Jyseleca®). HTA ID: 21048](https://www.ncpe.ie/filgotinib-jyseleca-hta-id21048/)
- [Fedratinib (Inrebic®). HTA ID: 21069](https://www.ncpe.ie/fedratinib-inrebic-hta-id-21069/)
- [Estradiol (Oestrogel® Pump Gel). HTA ID: 20013](https://www.ncpe.ie/estradiol-oestrogel-pump-gel-hta-id-20013/)
- [Esketamine (Spravato®). HTA ID: 19055](https://www.ncpe.ie/esketamine-spravato-hta-id-19055/)
- [Erenumab (Aimovig®)](https://www.ncpe.ie/erenumab-aimovig/)
- [Enzalutamide (Xtandi®) for nmCRPC. HTA ID: 18056](https://www.ncpe.ie/enzalutamide-xtandi-for-nmcrpc/)
- [Enzalutamide (Xtandi®) for mHSPC. HTA ID: 21022](https://www.ncpe.ie/enzalutamide-xtandi-for-mhspc-hta-id-21022/)
- [Durvalumab (Imfinzi®) for 1L extensive-stage small cell lung cancer. HTA ID: 21033](https://www.ncpe.ie/durvalumab-imfinzi-for-1l-extensive-stage-small-cell-lung-cancer-hta-id-21033/)
- [Ceftazidime/avibactam (Zavicefta®). HTA ID: 21003](https://www.ncpe.ie/ceftazidime-avibactam-zavicefta-hta-id-21003/)
- [Brigatinib (Alunbrig®). HTA ID: 20031](https://www.ncpe.ie/brigatinib-alunbrig-hta-id-20031/)
- [Brentuximab vedotin (Adcetris®). HTA ID: 21010](https://www.ncpe.ie/brentuximab-vedotin-adcetris-hta-id-21010/)
- [Benralizumab (Fasenra®) Autoinjector. HTA ID: 20018](https://www.ncpe.ie/benralizumab-fasenra-autoinjector-ht-application-hta-id-20018/)
- [Avatrombopag (Doptelet®). HTA ID: 20006](https://www.ncpe.ie/avatrombopag-doptelet-hta-id-20006/)
- [Atezolizumab (Tecentriq®) for 1L NSCLC. HTA ID: 21012](https://www.ncpe.ie/atezolizumab-tecentriq-hta-id-21012/)
- [Atezolizumab (Tecentriq®). HTA ID: 20039](https://www.ncpe.ie/atezolizumab-tecentriq-hta-id-20039/)
- [Anakinra (Kineret®). HTA ID: 22059](https://www.ncpe.ie/anakinra-kineret-hta-id-22059/)
- [Alutard SQ® honey bee and Alutard SQ® wasp venoms. HTA ID: 19038](https://www.ncpe.ie/alutard-sq-honey-bee-and-alutard-sq-wasp-venoms-hta-id-19038/)
- [Abemaciclib (Verzenios®). HTA ID: 20033](https://www.ncpe.ie/abemaciclib-verzenios-hta-id-20033/)
- [Update to Full Submission Template](https://www.ncpe.ie/update-to-full-submission-template/)
- [Emtricitabine/tenofovir disoproxil (TEVA®)](https://www.ncpe.ie/emtricitabine-tenovir-disoproxil-teva/) - NCPE Pharmacoeconomic Evaluation Emtricitabine/tenofovir disoproxil (TEVA®)
- [Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (Stribild®)](https://www.ncpe.ie/stribild-elvitegravircobicistatemtricitabinetenofovir-disoproxil-as-fumarate/)
- [Tadalafil (Adcirca®)](https://www.ncpe.ie/tadalafil-adcirca-2/) - NCPE Pharmacoeconomic Evaluation Tadalafil (Adcirca®)
- [Crizotinib (Xalkori®) for ROS1 NSCLC](https://www.ncpe.ie/crizotinib-xalkori-for-ros1-nsclc/) - NCPE Pharmacoeconomic Evaluation Crizotinib (Xalkori®) for ROS1 NSCLC
- [Crizotinib (Xalkori®) for first line ALK+ NSCLC](https://www.ncpe.ie/crizotinib-xalkori-for-first-line-alk-nsclc/) - NCPE Pharmacoeconomic Evaluation Crizotinib (Xalkori®)for first line ALK+ NSCLC
- [Corifollitropin alfa (Elonva®)](https://www.ncpe.ie/corifollitropin-alfa-elonva/) - NCPE Pharmacoeconomic Evaluation Corifollitropin alfa (Elonva®)
- [Conestat alfa (Ruconest®). HTA ID: 21017](https://www.ncpe.ie/conestat-alfa-ruconest-hta-id-21017/)
- [Collagenase Clostridium Histolyticum (Xiapex®)](https://www.ncpe.ie/collagenase-clostridium-histolyticum-xiapex/) - NCPE Pharmacoeconomic Evaluation Collagenase Clostridium Histolyticum (Xiapex®)
- [Colistimethate sodium (Colobreathe®)](https://www.ncpe.ie/colistimethate-sodium-colobreathe/) - NCPE Pharmacoeconomic Evaluation Colistimethate sodium (Colobreathe®)
- [Colesevelam (Cholestagel®)](https://www.ncpe.ie/colesevelam-cholestagel/) - NCPE Pharmacoeconomic Evaluation Colesevelam (Cholestagel®)
- [Co-enzyme Q10 (CoQun®). HTA ID: 19045](https://www.ncpe.ie/co-enzyme-q10-coqun-hta-id-19045/) - NCPE Pharmacoeconomic Evaluation Co-enzyme Q10 (CoQun®)
- [Clindamycin 1% with tretinoin 0.025% (Treclinac®)](https://www.ncpe.ie/clindamycin-1-with-tretinoin-0-025-treclinac/) - NCPE Pharmacoeconomic Evaluation Clindamycin 1% with tretinoin 0.025% (Treclinac®)
- [Ciclosporin 1mg/ml eye drops (Ikervis®)](https://www.ncpe.ie/ciclosporin-1mgml-eye-drops-ikervis/) - NCPE Pharmacoeconomic Evaluation Ciclosporin 1mg/ml eye drops (Ikervis®)
- [Cholic acid (Orphacol®). HTA ID: 21062](https://www.ncpe.ie/cholic-acid-orphacol-hta-id-21062/)
- [Certolizumab pegol (Cimzia ®) for moderate to severe plaque psoriasis](https://www.ncpe.ie/certolizumab-pegol-cimzia-for-moderate-to-severe-plaque-psoriasis/)
- [Ceritinib (Zykadia®)](https://www.ncpe.ie/ceritinib-zykadia/) - NCPE Pharmacoeconomic Evaluation Ceritinib (Zykadia®)
- [Ceftazidime/avibactam (Zavicefta®)](https://www.ncpe.ie/ceftazidime-avibactam-cef-avizavicefta/) - NCPE Pharmacoeconomic Evaluation ceftazidime-avibactam (CEF-AVI)(Zavicefta®)
- [Catumaxomab (Removab®)](https://www.ncpe.ie/catumaxomab-removab/) - NCPE Pharmacoeconomic Evaluation Catumaxomab (Removab®)
- [Casirivimab/imdevimab (Ronapreve®). HTA ID: 21067](https://www.ncpe.ie/casirivimab-imdevimab-ronapreve-hta-id-21067/)
- [Cariprazine (Reagila®)](https://www.ncpe.ie/cariprazine-reagila/)
- [Carfilzomib (Kyprolis®) in combination with dexamethasone (CAR+DEX).](https://www.ncpe.ie/carfilzomib-kyprolis-in-combination-with-dexamethasone-cardex/)
- [Pembrolizumab (Keytruda®) for Adjuvant melanoma](https://www.ncpe.ie/pembrolizumab-keytruda-for-adjuvant-melanoma/)
- [Selexipag (Uptravi®)](https://www.ncpe.ie/selexipag-uptravi/) - NCPE Pharmacoeconomic Evaluation Selexipag (Uptravi®)
- [Secukinumab (Cosentyx®) for moderate to severe plaque psoriasis](https://www.ncpe.ie/secukinumab-cosentyx/) - NCPE Pharmacoeconomic Evaluation Secukinumab (Cosentyx®)
- [Calcipotriol/Betamethasone dipropionate (Enstilar ®)](https://www.ncpe.ie/calcipotriol-and-betamethasone-dipropionate-cutaneous-foam-enstilar/) - NCPE Pharmacoeconomic Evaluation Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar ®)
- [Sebelipase alfa (Kanuma®)](https://www.ncpe.ie/sebelipase-alfa-kanuma/) - NCPE Pharmacoeconomic Evaluation Sebelipase alfa (Kanuma®)
- [Ceftolozane/tazobactam (Zerbaxa®)](https://www.ncpe.ie/ceftolozanetazobactam-zerbaxa/) - NCPE Pharmacoeconomic Evaluation Ceftolozane/tazobactam (Zerbaxa®)
- [Roflumilast (Daxas®)](https://www.ncpe.ie/roflumilast-daxas/) - The NCPE do not recommend reimbursement of Roflumilast (Daxas®) under the Community Drugs Schelmes.
- [Rivaroxaban (Xarelto®) for the Treatment of Deep Vein Thrombosis](https://www.ncpe.ie/rivaroxaban-xarelto-for-dvt/) - The NCPE consider that at the submitted price Rivaroxaban could be considered cost-effective for this indication.
- [Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement](https://www.ncpe.ie/rivaroxaban-xarelto/) - NCPE Pharmacoeconomic Evaluation Rivaroxaban (Xarelto®)
- [Rivaroxaban (Xarelto®) for the Prevention of Stroke in Atrial Fibrillation](https://www.ncpe.ie/rivaroxaban-xarelto-for-spaf-2/) - NCPE Pharmacoeconomic Evaluation Rivaroxaban (Xarelto®) spAF
- [Rivaroxaban (Xarelto®) for the prevention of atherothrombotic events](https://www.ncpe.ie/rivaroxaban-xarelto-for-the-prevention-of-atherothrombotic-events/)
- [Ramucirumab (Cyramza®)](https://www.ncpe.ie/ramucirumab-cyramza/) - NCPE Pharmacoeconomic Evaluation Ramucirumab (Cyramza®)
- [Radium-223 (Xofigo®)](https://www.ncpe.ie/radium-223-xofigo/) - NCPE Pharmacoeconomic Evaluation Radium-223 (Xofigo®)
- [Ruxolitinib (Jakavi®)](https://www.ncpe.ie/ruxolitinib-jakavi/) - NCPE Pharmacoeconomic Evaluation Ruxolitinib (Jakavi®)
- [Sapropterin (Kuvan®)](https://www.ncpe.ie/sapropterin-kuvan/) - NCPE Pharmacoeconomic Evaluation Sapropterin (Kuvan®)
- [Simeprevir (Olysio®)](https://www.ncpe.ie/simeprevir-olysio-in-combination-with-sofosbuvir/) - Pharmacoeconomic Evaluation of Simeprevir (Olysio®)
- [Brentuximab vedotin (Adcetris®) for CD30+ cutaneous T-cell lymphoma (CTCL)](https://www.ncpe.ie/brentuximab-vedotin-adcetris-for-cd30-cutaneous-t-cell-lymphoma-ctcl/) - NCPE Pharmacoeconomic Evaluation Brentuximab vedotin (Adcetris®)
- [Ketoconazole (Ketoconazole HRA®). HTA ID: 21046](https://www.ncpe.ie/ketoconazole-ketoconazole-hra-hta-id-21046/)
- [Dimethyl fumarate (Skilarence®)](https://www.ncpe.ie/dimethyl-fumarate-skilarence/) - NCPE Pharmacoeconomic Evaluation Dimethyl fumarate (Skilarence®)
- [Dapagliflozin (Forxiga®)](https://www.ncpe.ie/dapagliflozin-forxiga/) - NCPE Pharmacoeconomic Evaluation Dapagliflozin (Forxiga®)
- [Sunitinib (Sutent®)](https://www.ncpe.ie/sunitinib-sutent/) - NCPE Pharmacoeconomic Evaluation of Sunitinib (Sutent®)
- [Sufentanil (Zalviso®)](https://www.ncpe.ie/sufentanil-zalviso/) - NCPE Pharmacoeconomic Evaluation Sufentanil (Zalviso®)
- [Sublingual Immunotherapy (Grazax®)](https://www.ncpe.ie/sublingual-immunotherapy-grazax/) - NCPE Pharmacoeconomic Evaluation Sublingual Immunotherapy (Grazax®)
- [Stiripentol (Diacomit®)](https://www.ncpe.ie/stiripentol-diacomit/)
- [Sofosbuvir/Velpatasvir (Epclusa®)](https://www.ncpe.ie/sofosbuvirvelpatasvir-epclusa/) - Pharmacoeconomic Evaluation of Sofosbuvir/Velpatasvir (Epclusa®) for the treatment of chronic hepatitis C virus (HCV) infection in adults
- [Sofosbuvir (Solvaldi®)](https://www.ncpe.ie/sofosbuvir-solvaldi/) - NCPE Pharmacoeconomic Evaluation Sofosbuvir (Solvaldi®)
- [Ulipristal acetate (Esmya ®) intermittent treatment](https://www.ncpe.ie/ulipristal-acetate-esmya-2/) - NCPE Pharmacoeconomic Evaluation Ulipristal acetate (Esmya ®)
- [Vortioxetine (Brintellix®)](https://www.ncpe.ie/vortioxetine-brintellix/) - NCPE Pharmacoeconomic Evaluation Vortioxetine (Brintellix®)
- [Vismodegib (Erivedge®)](https://www.ncpe.ie/vismodegib-erivedge/) - NCPE Pharmacoeconomic Evaluation Vismodegib (Erivedge®)
- [Vestronidase alfa (MEPSEVII®)](https://www.ncpe.ie/vestronidase-alfa-mepsevii/)
- [Vernakalant (Brinavess®)](https://www.ncpe.ie/vernakalant-brinavess/) - The NCPE recommend reimbursement of Vernakalant (Brinavess®) in the hospital setting
- [Venetoclax (Venclyxto®) in combination with rituximab](https://www.ncpe.ie/venetoclax-venclyxto-in-combination-with-rituximab/)
- [Ertugliflozin (Steglatro®)](https://www.ncpe.ie/ertugliflozin-steglatro/) - NCPE Pharmacoeconomic Evaluation Ertugliflozin (Steglatro®)
- [Enzalutamide (Xtandi®)  pre chemotherapy](https://www.ncpe.ie/enzalutamide-xtandi-pre-chemotherapy/)
- [Eltrombopag (Revolade®)](https://www.ncpe.ie/eltrombopag-revolade/) - The NCPE do not recommend the reimbursement of Eltrombopag (Revolade®) under the High Tech Drug Scheme.
- [Elosulfase alfa (Vimizim®)](https://www.ncpe.ie/elosulfase-alfa-vimizim/) - NCPE Pharmacoeconomic Evaluation Elosulfase alfa (Vimzim®)
- [Evolocumab (Repatha®)](https://www.ncpe.ie/evolocumab-repatha/)
- [Zanamivir (Dectova®)](https://www.ncpe.ie/zanamivir-dectova/)
- [Eliglustat (Cerdelga®)](https://www.ncpe.ie/eliglustat-cerdelga/) - NCPE Pharmacoeconomic Evaluation Eliglustat (Cerdelga®)
- [Eculizumab (Soliris®)](https://www.ncpe.ie/eculizumab-soliris/) - NCPE Pharmacoeconomic Evaluation Eculizumab (Soliris®)
- [Fidaxomicin (Dificlir®)](https://www.ncpe.ie/fidaxomicin-dificlir/)
- [Human alpha1-proteinase inhibitor (Respreeza®)](https://www.ncpe.ie/human-alpha1-proteinase-inhibitor-respreeza/) - NCPE Pharmacoeconomic Evaluation Human alpha1-proteinase inhibitor (Respreeza®)
- [Vemurafenib (Zelboraf®)](https://www.ncpe.ie/vermurafenib-zelboraf/) - NCPE Pharmacoeconomic Evaluation Vermurafenib (Zelboraf®)
- [Vedolizumab (Entyvio®) in Ulcerative Colitis](https://www.ncpe.ie/vedolizumab-entyvio-in-ulcerative-colitis/) - NCPE Pharmacoeconomic Evaluation Vedolizumab (Entyvio®)
- [Vedolizumab (Entyvio®) in Crohn’s Disease](https://www.ncpe.ie/vedolizumab-entyvio-in-crohns-disease/) - NCPE Pharmacoeconomic Evaluation Vedolizumab (Entyvio®)
- [Sacubitril/valsartan (Entresto®)](https://www.ncpe.ie/sacubitrilvalsartan-entresto/) - NCPE Pharmacoeconomic Evaluation Sacubitril/Valsartan (Entresto®)
- [Ustekinumab (Stelara®)](https://www.ncpe.ie/ustekinumab-stelara/) - NCPE Pharmacoeconomic Evaluation Ustekinumab (Stelara®)
- [Update to Submission Templates](https://www.ncpe.ie/update-to-submission-templates/)
- [Updated NCPE Rapid Review Applicant Submission Template](https://www.ncpe.ie/updated-ncpe-rapid-review-applicant-submission-template/)
- [Pneumococcal conjugate vaccine](https://www.ncpe.ie/pneumococcal-conjugate-vaccine-2/)
- [Rotavirus Vaccine](https://www.ncpe.ie/rotavirus-vaccine-2/)
- [Universal Infant Hepatitis B Vaccination programme](https://www.ncpe.ie/universal-infant-hepatitis-b-vaccination-programme-2/)
- [Oncotype DX®](https://www.ncpe.ie/oncotype-dx-2/)
- [Carglumic acid (Ucedane®). HTA ID: 22035](https://www.ncpe.ie/carglumic-acid-ucedane-hta-id-22035/)
- [Buprenorphine and naloxone (Zubsolv®). HTA ID: 22037](https://www.ncpe.ie/buprenorphine-and-naloxone-zubsolv-hta-id-22037/)
- [Capsaicin (Qutenza®)](https://www.ncpe.ie/capsaicin-8ww-patch-qutenza/)
- [St Johns Wort (Pacifa®)](https://www.ncpe.ie/st-johns-wort-pafica/) - NCPE Pharmacoeconomic Evaluation St Johns Wort (Pafica®)
- [Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®)](https://www.ncpe.ie/sofosbuvirvelpatasvirvoxilaprevir-vosevi/) - NCPE Pharmacoeconomic Evaluation Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®)
- [Sofosbuvir/Velpatasvir (Epclusa®) chronic hepatitis C virus (HCV) - pangenotypic](https://www.ncpe.ie/sofosbuvirvelpatasvir-epclusa-chronic-hepatitis-c-virus-hcv-pangenotypic/) - NCPE Pharmacoeconomic Evaluation Sofosbuvir/Velpatasvir (Epclusa®)
- [Sodium phenylbutyrate (Pheburane®)](https://www.ncpe.ie/sodium-phenylbutyrate-pheburane/) - NCPE Pharmacoeconomic Assesment Sodium phenylbutyrate (Pheburane®)
- [Sodium Hyaluronate (Hylotear® 0.1%)](https://www.ncpe.ie/sodium-hyaluronate-hylotear-0-1/) - NCPE Pharmacoeconomic Evaluation Sodium Hyaluronate (Hylotear® 0.1%)
- [Sodium Hyaluronate (Hyloforte® 0.2%)](https://www.ncpe.ie/sodium-hyaluronate-hyloforte-0-2/) - NCPE Pharmacoeconomic Evaluation Sodium Hyaluronate (Hyloforte® 0.2%)
- [Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb®)](https://www.ncpe.ie/sodium-chloride-70mgml-sodium-hyaluronate-1mgml-hyaneb/) - NCPE Pharmacoeconomic Evaluation Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb®)
- [Camellia sinensis, folium (green tea leaf) (Catephen®)](https://www.ncpe.ie/camellia-sinensis-folium-green-tea-leaf-catephen-10/) - NCPE Pharmacoeconomic Evaluation Camellia sinensis, folium (green tea leaf) (Catephen 10%®)
- [Venetoclax (Venclyxto®)](https://www.ncpe.ie/venetoclax-venclyxto/) - NCPE Pharmacoeconomic Evaluation Venetoclax (Venclyxto®)
- [Velaglucerase Alfa (VPRIV®)](https://www.ncpe.ie/velaglucerase-alfa-vpriv-2/) - NCPE Pharmacoeconomic Evaluation Velaglucerase Alfa (VPRIV®)
- [Vandetanib (Caprelsa®)](https://www.ncpe.ie/vandetanib-caprelsa/) - NCPE Pharmacoeconomic Evaluation Vandetanib (Caprelsa®)
- [Ustekinumab (Stelara®) for Crohn's Disease](https://www.ncpe.ie/ustekinumab-stelara-2/) - NCPE Pharmacoeconomic Evaluation Ustekinumab (Stelara®)
- [Urea (GlucoRx Allpresan®)](https://www.ncpe.ie/urea-glucorx-allpresan/)
- [Umeclidinium/vilanterol (Anoro®)](https://www.ncpe.ie/umeclidiniumvilanterol-anoro/) - NCPE Pharmacoeconomic Evaluation Umeclidinium/vilanterol (Anoro®)
- [Ulipristal acetate (Esmya®) single course treatment](https://www.ncpe.ie/ulipristal-acetate-esmya/) - NCPE Pharmacoeconomic Evaluation Ulipristal acetate (Esmya®)
- [Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim®)](https://www.ncpe.ie/eurartesim-piperaquine-tetraphosphatedihidroartemisinin/)
- [Exenatide (Bydureon®)](https://www.ncpe.ie/exenatide-bydureon/) - NCPE Pharmacoeconomic Evaluation Exenatide (Bydureon®)
- [Everolimus (Votubia®)](https://www.ncpe.ie/everolimus-votubia/) - Pharmacoeconomic Evaluation of Everolimus (Votubia®)
- [Everolimus (Votubia ®) for refractory seizures associated with tuberous sclerosis complex (TSC)](https://www.ncpe.ie/everolimus-votubia-for-refractory-seizures-associated-with-tuberous-sclerosis-complex-tsc/) - NCPE Pharmacoeconomic Evaluation Everolimus (Votubia ®)
- [Everolimus (Afinitor®)](https://www.ncpe.ie/everolimus-afinitor/) - NCPE Pharmacoeconomic Evaluation Everolimus (Afinitor®)
- [Etelcalcetide (Parsabiv®)](https://www.ncpe.ie/etelcalcetide-parsabiv/) - NCPE Pharmacoeconomic Evaluation Etelcalcetide (Parsabiv®)
- [Etanercept (Benepali®)](https://www.ncpe.ie/etanercept-benepali/) - NCPE Pharmacoeconomic Evaluation Etanercept (Benepali®)
- [Eslicarbazepine (Zebinix®)](https://www.ncpe.ie/eslicarbazepine-zebinix/) - NCPE Pharmacoeconomic Evaluation Eslicarbazepine (Zebinix®)
- [Inclisiran (Leqvio®). HTA ID: 20051](https://www.ncpe.ie/inclisiran-leqvio-hta-id-20051/)
- [Epoprostenol (Veletri®)](https://www.ncpe.ie/epoprostenol-veletri/) - NCPE Pharmacoeconomic Evaluation Epoprostenol (Veletri®)
- [Trifluridine/tipiracil (Lonsurf®)](https://www.ncpe.ie/trifluridinetipiracil-lonsurf/) - NCPE Pharmacoeconomic Evaluation Trifluridine/tipiracil (Lonsurf®)
- [Trientine Tetrahydrochloride (TETA 4HCL) – Cuprior®](https://www.ncpe.ie/trientine-tetrahydrochloride-teta-4hcl-cuprior/)
- [Trastuzumab emtansine (Kadcyla®) HTA ID: 20002](https://www.ncpe.ie/trastuzumab-emtansine-kadcyla-hta-id-20002/)
- [Trastuzumab emtansine (Kadcyla®)](https://www.ncpe.ie/trastuzumab-emtansine-kadcyla/) - NCPE Pharmacoeconomic Evaluation Trastuzumab emtansine (Kadcyla®)
- [Trametinib (Mekinist®)](https://www.ncpe.ie/trametinib-mekinist/) - NCPE Pharmacoeconomic Evaluation Trametinib (Mekinist®)
- [Tramadol hydrochloride/dexketoprofen (Skudexa®)](https://www.ncpe.ie/tramadol-hydrochloridedexketoprofen-skudexa/) - NCPE Pharmacoeconomic Evaluation Tramadol hydrochloride/dexketoprofen (Skudexa®)
- [Emtricitabine/tenofovir alafenamide (Descovy®)](https://www.ncpe.ie/emtricitabinetenofovir-alafenamide-descovy/) - NCPE Pharmacoeconomic Evaluation Emtricitabine/tenofovir alafenamide (Descovy®)
- [Tralokinumab (Adtralza®). HTA ID: 21028](https://www.ncpe.ie/tralokinumab-adtralza-hta-id-21028/)
- [Eltrombopag (Revolade®)](https://www.ncpe.ie/eltrombopag-revolade-2/)
- [Tolvaptan (Jinarc®)](https://www.ncpe.ie/tolvaptan-jinarc/) - NCPE Pharmacoeconomic Evaluation Tolvaptan (Jinarc®)
- [Tofacitinib (Xeljanz®) for Ulcerative Colitis](https://www.ncpe.ie/tofacitinib-xeljanz-for-ulcerative-colitis/)
- [Tofacitinib (Xeljanz®) for ankylosing spondylitis. HTA ID: 22005](https://www.ncpe.ie/tofacitinib-xeljanz-for-ankylosing-spondylitis-hta-id-22005/)
- [Tofacitinib (Xeljanz®) for active polyarticular juvenile idiopathic arthritis. HTA ID: 21034](https://www.ncpe.ie/tofacitinib-xeljanz-for-active-polyarticular-juvenile-idiopathic-arthritis-hta-id-21034/)
- [Tocilizumab SC (RoActemra®)](https://www.ncpe.ie/tocilizumab-sc-roactemra/) - Pharmacoeconomic Evaluation of Tocilizumab SC (RoActemra®)
- [Modified Release Hydrocortisone  (Plenadren®)](https://www.ncpe.ie/hydrocortisone-plenadren/) - NCPE Pharmacoeconomic Evaluation Hydrocortisone (Plenadren®)
- [Follitropin delta (Rekovelle®)](https://www.ncpe.ie/follitropin-delta-rekovelle/) - NCPE Pharmacoeconomic Evaluation Follitropin delta (Rekovelle®
- [Tobramycin (TOBI Podhaler®)](https://www.ncpe.ie/tobramycin-tobi-podhaler/) - Tobramycin (TOBI Podhaler®)
- [Tixagevimab/cilgavimab (Evusheld®).HTA ID: 22074](https://www.ncpe.ie/tixagevimab-cilgavimab-evusheld-hta-id-22074/)
- [Tivozanib (Fotivda®)](https://www.ncpe.ie/tivozanib-fotivda/)
- [Tisagenlecleucel (Kymriah®) for pALL](https://www.ncpe.ie/tisagenlecleucel-kymriah-for-all/)
- [Tisagenlecleucel (Kymriah®) for DLBCL](https://www.ncpe.ie/tisagenlecleucel-kymriah-for-dlbcl/)
- [Tirbanibulin (Klisyri®). HTA ID: 21054](https://www.ncpe.ie/tirbanibulin-klisyri-hta-id-21054/)
- [Tildrakizumab (Ilumetri®). HTA ID: 19029](https://www.ncpe.ie/tildrakizumab-ilumetri/)
- [Ticagrelor (Brilique®)](https://www.ncpe.ie/ticagrelor-brilique/) - The NCPE consider Tigcagrelor (Brilique®) a cost effective therapy for the prevention of atherothrombotic events in adult patients with ACS including patients managed medically and those managed with PCI or CABG
- [Ticagrelor (Brilique®) in combination with acetylsalicyclic acid](https://www.ncpe.ie/ticagrelor-brilique-2/) - NCPE Pharmacoeconomic Evaluation Ticagrelor (Brilique®)
- [Simeprevir (Olysio®)](https://www.ncpe.ie/simeprevir-olysio/)
- [Teriflunomide (Aubagio®)](https://www.ncpe.ie/teriflunomide-aubagio/)
- [Sildenafil (Revatio®)](https://www.ncpe.ie/sildenafil-revatio/) - NCPE Pharmacoeconomic Evaluation Sildenafil (Revatio®)
- [Semaglutide (Ozempic®)](https://www.ncpe.ie/semaglutide-ozempic/) - NCPE Pharmacoeconomic Evaluation Semaglutide (Ozempic®)
- [Secukinumab (Cosentyx®) for Psoriatic Arthritis](https://www.ncpe.ie/secukinumab-cosentyx-for-psoriatic-arthritis/)
- [Secukinumab (Cosentyx®) for Ankylosing Spondylitis](https://www.ncpe.ie/secukinumab-cosentyx-for-ankylosing-spondylitis/) - NCPE Pharmacoeconomic Evaluation Secukinumab (Cosentyx®)
- [Sarilumab (Kevzara®)](https://www.ncpe.ie/sarilumab-kevzara/) - NCPE Pharmacoeconomic Evaluation Sarilumab (Kevzara®)
- [Safinamide methansulfonate (Xadago®)](https://www.ncpe.ie/safinamide-methansulfonate-xadago/) - NCPE Pharmacoeconomic Evaluation Safinamide methansulfonate (Xadago®)
- [Telavancin (Vibativ®)](https://www.ncpe.ie/telavancin-vibativ/) - NCPE Pharmacoeconomic Evaluation Telavancin (Vibativ®)
- [Telaprevir (Incivo®)](https://www.ncpe.ie/telapravir/) - The NCPE consider telaprevir (Incivo®) a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting.
- [Tegafur/Gimeracil/Oteracil (Teysuno®)](https://www.ncpe.ie/tegafurgimeraciloteracil-teysuno/)
- [Teduglutide (Revestive®)](https://www.ncpe.ie/teduglutide-revestive/) - NCPE Pharmacoeconomic Evaluation Teduglutide (Revestive®)
- [Tedizolid phosphate (Sivextro®)](https://www.ncpe.ie/tedizolid-phosphate-sivextro/)
- [Tapentadol (Palexia®)](https://www.ncpe.ie/tapentadol-palexia/) - Tapentadol (Palexia®)
- [Talimogene laherparepvec (Imlygic®)](https://www.ncpe.ie/talimogene-laherparepvec-imlygic/) - NCPE Pharmacoeconomic Evaluation Talimogene Laherparepvec (Imlygic®)
- [Talazoparib (Talzenna®) HTA ID: 19032](https://www.ncpe.ie/talazoparib-talzenna/)
- [Tafluprost (Saflutan®)](https://www.ncpe.ie/tafluprost-saflutan/) - NCPE Pharmacoeconomic Evaluation Tafluprost (Saflutan®)
- [Tafamidis meglumine (Vyndaqel®)](https://www.ncpe.ie/tafamadis-meglumine-vyndaqel/) - NCPE Pharmacoeconomic Evaluation Tafamadis meglumine (Vyndaqel®)
- [Tafamidis (Vyndaqel®). HTA ID: 20017](https://www.ncpe.ie/tafamidis-vindaqel-hta-id-20017/)
- [Pembrolizumab (Keytruda®) 1L NSCLC with chemotherapy](https://www.ncpe.ie/pembrolizumab-keytruda-1l-nsclc-with-chemotherapy/) - NCPE Pharmacoeconomic Evaluation Pembrolizumab (Keytruda®) 1L NSCLC with chemotherapy
- [Pembrolizumab (Keytruda®) for Urothelial Carcinoma 2L](https://www.ncpe.ie/pembrolizumab-keytruda-for-urothelial-carcinoma-2l/) - NCPE Pharmacoeconomic Evaluation Pembrolizumab (Keytruda ®)
- [Pembrolizumab (Keytruda ®) for Urothelial  Carcinoma 1L](https://www.ncpe.ie/pembrolizumab-keytruda-for-uc-1l/) - NCPE Pharmacoeconomic Evaluation Pembrolizumab (Keytruda®)
- [Pembrolizumab (Keytruda®) for Classical Hodgkin Lymphoma](https://www.ncpe.ie/pembrolizumab-keytruda-for-classical-hodgkin-lymphoma/) - NCPE Pharmacoeconomic Evaluation Pembrolizumab (Keytruda®)
- [Pembrolizumab (Keytruda®) 1L squamous NSCLC with chemotherapy](https://www.ncpe.ie/pembrolizumab-keytruda-1l-squamous-nsclc-with-chemotherapy/)
- [Romiplostim (Nplate®)](https://www.ncpe.ie/romiplostim-nplate-2/)
- [Romiplostim (Nplate®)](https://www.ncpe.ie/romiplostim-nplate/) - NCPE Pharmacoeconomic Evaluation Romiplostim (Nplate®)
- [Ropivacaine Readyfusor®](https://www.ncpe.ie/ropivacaine-readyfusor/)
- [Pegylated Interferon beta-1a (Plegridy®)](https://www.ncpe.ie/pegylated-interferon-b-1a-plegridy/) - NCPE Pharmacoeconomic Evaluation Pegylated Interferon beta-1a (Plegridy ®)
- [Hydroxycarbamide solution (Xromi®). HTA ID: 20020](https://www.ncpe.ie/hydroxycarbamide-solution-xromi-hta-id-20020/)
- [Hydroxycarbamide (Siklos®)](https://www.ncpe.ie/hydroxcarbamide-siklos/) - NCPE Pharmacoeconomic Evaluation Hydroxcarbamide (Siklos®)
- [Hydrocortisone modified-release hard capsules (Efmody®). HTA ID: 21042](https://www.ncpe.ie/hydrocortisone-modified-release-hard-capsules-efmody-hta-id-21042/)
- [Hyaluronic acid and co enzyme Q10 (VisuXL®)](https://www.ncpe.ie/hyaluronic-acid-and-co-enzyme-q10-visuxl/) - NCPE Pharmacoeconomic Evaluation Cross linked hyaluronic acid and co enzyme Q10 (VisuXL®)
- [Human alpha1-proteinase inhibitor (A1PI) (Prolastin®)](https://www.ncpe.ie/human-alpha1-proteinase-inhibitor-a1pi-prolastin/) - NCPE Pharmacoeconomic Evaluation Human alpha1-proteinase inhibitor (A1PI) (Prolastin®)
- [House Dust Mite Extract (Acarizax ®) for Allergic Rhinitis. HTA ID: 20015](https://www.ncpe.ie/house-dust-mite-extract-acarizax-for-allergic-rhinitis-hta-id-20015/)
- [Pegvaliase (Palynziq®) HTA ID: 21057](https://www.ncpe.ie/pegvaliase-palynziq-hta-id-21057/)
- [Rolapitant (Varuby®)](https://www.ncpe.ie/rolapitant-varuby/) - NCPE Pharmacoeconomic Evaluation Rolapitant (Varuby®)
- [Guselkumab (Tremfya®)](https://www.ncpe.ie/guselkumab-tremfya/) - NCPE Pharmacoeconomic Evaluation Guselkumab (Tremfya®)
- [Guanfacine hydrochloride (Intuniv®)](https://www.ncpe.ie/guanfacine-hydrochloride-intuniv/) - NCPE Pharmacoeconomic Evaluation Guanfacine hydrochloride (Intuniv®)
- [Rivaroxaban (Xarelto®) low dose for prevention of recurrent venous thromboembolism](https://www.ncpe.ie/rivaroxaban-xarelto-low-dose-for-prevention-of-recurrent-venous-thromboembolism/) - NCPE Pharmacoeconomic Evaluation Rivaroxaban (Xarelto®)
- [Grass pollen allergen extract (Oralair®)](https://www.ncpe.ie/grass-pollen-allergen-extract-oralair/) - NCPE Pharmacoeconomic Evaluation Grass pollen allergen extract (Oralair®)
- [Golimumab (Simponi®) for UC](https://www.ncpe.ie/golimumab-simponi-2/) - NCPE Pharmacoeconomic Evaluation Golimumab (Simponi®)
- [Pegaspargase (Oncaspar®) powder for solution for injection/infusion. HTA ID: 20003](https://www.ncpe.ie/pegaspargase-oncaspar-powder-for-solution-for-injection-infusion-hta-id-20003/)
- [Patisiran (Onpattro®)](https://www.ncpe.ie/patisiran-onpattro/)
- [Rivaroxaban (Xarelto®) for Atrial Fibrillation patients undergoing PCI](https://www.ncpe.ie/rivaroxaban-xarelto-for-atrial-fibrillation-patients-undergoing-pci/) - NCPE Pharmacoeconomic Evaluation Rivaroxaban (Xarelto®)
- [Rituximab (MabThera®)](https://www.ncpe.ie/rituximab-mabthera/) - NCPE Pharmacoeconomic Evaluation Rituximab (MabThera®)
- [Riociguat (Adempas®)](https://www.ncpe.ie/riociguat-adempas/) - NCPE Pharmacoeconomic Evaluation Riociguat (Adempas®)
- [Rimonabant (Acomplia®)](https://www.ncpe.ie/rimonabant-acomplia-2/)
- [Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey®)](https://www.ncpe.ie/rilpivirine-r-emtricitabine-f-tenofovir-alafenamide-taf-odefsey/) - NCPE Pharmacoeconomic Evaluation Rilpivirine (R ), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey®)
- [Rilpivirine (Edurant®)](https://www.ncpe.ie/rilpivirine-edurant/) - NCPE Pharmacoeconomic Evaluation Rilpivirine (Edurant®)
- [Rifaximin (Targaxan®)](https://www.ncpe.ie/rifaximin-targaxan-2/) - NCPE Pharmacoeconomic Evaluation Rifaximin (Targaxan®)
- [Ribociclib (Kisqali®) – Updated License](https://www.ncpe.ie/ribociclib-kisqali-updated-license/)
- [Ribociclib (Kisqali®)](https://www.ncpe.ie/ribociclib-kisqali/) - NCPE Pharmacoeconomic Evaluation Ribociclib (Kisqali®)
- [Encorafenib (Braftovi®), binimetinib (Mektovi®)](https://www.ncpe.ie/encorafenib-braftovi-binimetinib-mektovi/)
- [Retigabine (Trobalt®)](https://www.ncpe.ie/retigabine-trobalt/) - NCPE Pharmacoeconomic Evaluation Retigabine (Trobalt®)
- [Elbasvir/Grazoprevir (Zepatier®)](https://www.ncpe.ie/elbasvirgrazoprevir-zepatier-2/) - NCPE Pharmacoeconomic Evaluation Elbasvir/Grazoprevir (Zepatier®)
- [Reslizumab (Cinqaero®)](https://www.ncpe.ie/reslizumab-cinqaero/) - NCPE Pharmacoeconomic Evaluation Reslizumab (Cinqaero®)
- [Regorafenib (Stivarga®) for GIST](https://www.ncpe.ie/regorafenib-stivarga-for-gist/) - NCPE Pharmacoeconomic Evaluation Regorafenib (Stivarga®)
- [Regadenoson (Rapiscan®)](https://www.ncpe.ie/regadenoson-rapiscan/) - NCPE Pharmacoeconomic Evaluation Regadenoson (Rapiscan®)
- [Emtricitabine / tenofovir disoproxil fumarate (Truvada®)](https://www.ncpe.ie/emtricitabine-tenofovir-disoproxil-fumarate-truvada/) - NCPE Pharmacoeconomic Evaluation Emtricitabine / tenofovir disoproxil fumarate (Truvada®)
- [Recombinant Human Parathyroid Hormone](https://www.ncpe.ie/recombinant-human-parathyroid-hormone-natpar/) - Pharmacoeconmic evaluation of Recombinant Human Parathyroid Hormone (Natpar®) for adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
- [Empagliflozin (Jardiance®)](https://www.ncpe.ie/empagliflozin-jardiance/)
- [Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya®)](https://www.ncpe.ie/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya/) - NCPE Pharmacoeconomic Evaluation Elvitegravir,Cobicistat,Emtricitabine,Tenofovir alafenamide (Genvoya®)
- [Eltrombopag (Revolade®)](https://www.ncpe.ie/eltrombopag-revolade-3/) - NCPE Pharmacoeconomic Evaluation Eltrombopag (Revolade®)
- [Ranolazine (Ranexa®)](https://www.ncpe.ie/ranolazine-ranexa/) - NCPE Rapid Review of Ranolazine (Ranexa®)
- [Prucalopride (Resolor®)](https://www.ncpe.ie/prucalopride-resolor/) - NCPE Pharmacoeconomic Evaluation Prucalopride (Resolor®)
- [Progesterone (micronised) (Utrogestan®)](https://www.ncpe.ie/progesterone-micronised-utrogestan/)
- [Pregabalin (Lyrica®) for the treatment of neuropathic pain](https://www.ncpe.ie/pregabalin-lyrica-2/) - NCPE Pharmacoeconomic Evaluation Pregabalin (Lyrica®)
- [Pregabalin (Lyrica®) for the treatment of Generalised Anxiety Disorder](https://www.ncpe.ie/pregabalin-lyrica-for-the-treatment-of-generalised-anxiety-disorder/)
- [Golimumab (Simponi®)](https://www.ncpe.ie/golimumab-simponi/) - NCPE Pharmacoeconomic Evaluation Golimumab (Simponi®)
- [Glycopyrronium bromide (Sialanar®)](https://www.ncpe.ie/glypyrronium-bromide-sialanar/)
- [Glycopyrronium bromide (Seebri Breezhaler®)](https://www.ncpe.ie/glycopyrronium-bromide-seebri-breezhaler/)
- [Glycerol Phenylbutyrate (Ravicti®)](https://www.ncpe.ie/glycerol-phenylbutyrate-ravicti/)
- [Glucosamine sulfate (Dona®)](https://www.ncpe.ie/glucosamine-sulfate-dona/) - The NCPE not believe that Glucosamine sulfate (DONA®) is a cost effective therapy for the treatment of osteoarthritis in the Irish Healthcare setting.
- [Edoxaban (Lixiana®)](https://www.ncpe.ie/edoxaban-lixiana/)
- [Cabozantinib (Cometriq®)](https://www.ncpe.ie/cabozantinib-cometriq/) - NCPE Rapid Review of Cabozantinib (COMETRIQ®). Full pharmacoeconomic evaluation recommended at the submitted price.
- [Pasireotide (Signifor®)](https://www.ncpe.ie/signifor-pasireotide/) - NCPE Pharmacoeconomic Evaluation Pasireotide (Signifor®)
- [Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax®) with or without dasabuvir (Exviera®)](https://www.ncpe.ie/paritaprevir-boosted-with-ritonavir-and-ombitasvir-vierkirax-with-or-without-dasabuvir-exviera/) - NCPE Pharmacoeconomic Evaluation Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax®) with or without dasabuvir (Exviera®)
- [Cabotegravir (Vocabria®) in combination with rilpivirine (Rekambys®). HTA ID: 21026](https://www.ncpe.ie/cabotegravir-vocabria-in-combination-with-rilpivirine-rekambys-hta-id-21026/)
- [Panobinostat (Farydak®)](https://www.ncpe.ie/panobinostat-farydak/) - NCPE Pharmacoeconomic Evaluation Panobinostat (Farydak®)
- [Paliperidone palmitate (Xeplion®)](https://www.ncpe.ie/paliperidone-palmitate-xeplion/) - NCPE Pharmacoeconomic Evaluation Paliperidone palmitate (Xeplion®)
- [Palbociclib (Ibrance®)](https://www.ncpe.ie/palbociclib-ibrance/) - NCPE Pharmacoeconomic Evaluation Palbociclib (Ibrance®)
- [Prasugrel (Efient®)](https://www.ncpe.ie/prasugrel-efient/) - NCPE Pharmacoeconomic Evaluation Prasugrel (Efient®)
- [C1inhibitor (human) (Cinryze®)](https://www.ncpe.ie/c1inhibitor-human-cinryze/) - NCPE Pharmacoeconomic Evaluation C1inhibitor (human) (Cinryze®)
- [Ponatinib (Iclusig®)](https://www.ncpe.ie/ponatinib-iclusig/) - NCPE Pharmacoeconomic Evaluation Ponatinib (Iclusig®)
- [Pomalidomide (Imnovid®)](https://www.ncpe.ie/pomalidomide-imnovid/) - NCPE Pharmacoeconomic Evaluation Pomalidomide (Imnovid®)
- [Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro®)](https://www.ncpe.ie/polynuclear-ironiii-oxyhydroxide-pn-feooh-velphoro/) - NCPE Pharmacoeconomic Evaluation Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro®)
- [Ozenoxacin (Dubine®)](https://www.ncpe.ie/ozenoxacin-dubine/)
- [Pixantrone (Pixuvri®)](https://www.ncpe.ie/pixantrone-pixuvri/) - NCPE Pharmacoeconomic Evaluation Pixantrone (Pixuvri®)
- [Pitolisant hydrochloride (Wakix®)](https://www.ncpe.ie/pitolisant-wakix/) - NCPE Pharmacoeconomic Evaluation Pitolisant hydrochloride (Wakix®)
- [Pitavastatin (Livazo®)](https://www.ncpe.ie/pitavastatin-livazo/) - NCPE Pharmacoeconomic Evaluation Pitavastatin (Livazo®)
- [Pirfenidone (Esbriet®)](https://www.ncpe.ie/pirfenidone-esbriet/) - NCPE Pharmacoeconomic Evaluation Pirfenidone (Esbriet®)
- [Oxycodone/naloxone (Targin®)](https://www.ncpe.ie/oral-oxycodonenaloxone-targin/) - NCPE Pharmacoeconomic Evaluation (Oral Oxydodone/naloxone (Targin®).
- [Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane®)](https://www.ncpe.ie/phenylephrine-hydrochloride-tropicamide-lidocaine-hydrochloride-fydrane/) - NCPE Pharmacoeconomic Evaluation Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane®)
- [Osimertinib (Tagrisso®) for the first-line treatment of metastatic NSCLC](https://www.ncpe.ie/osimertinib-tagrisso-for-the-first-line-treatment-of-metastatic-nsclc/)
- [Budesonide (Jorveza®)](https://www.ncpe.ie/budesonide-orodispersible-tablet-jorveza/)
- [Pertuzumab (Perjeta®) in neoadjuvant HER2 positive breast cancer](https://www.ncpe.ie/pertuzumab-perjeta-in-neoadjuvant-her2-positive-breast-cancer/) - NCPE Pharmacoeconomic Evaluation Pertuzumab (Perjeta®)
- [Brolucizumab (Beovu®). HTA ID: 20009](https://www.ncpe.ie/brolucizumab-beovu-hta-id-20009/)
- [Brodalumab (Kyntheum®)](https://www.ncpe.ie/brodalumab-kyntheum/)
- [Brivaracetam (Briviact®)](https://www.ncpe.ie/brivaracetam-briviact/) - NCPE Pharmacoeconomic Evaluation Brivaracetam (Briviact®)
- [Brimonidine (Mirvaso®)](https://www.ncpe.ie/brimonidine-3-3-mgg-gel-mirvaso/) - NCPE Pharmacoeconomic Evaluation Brimonidine 3.3 mg/g gel (Mirvaso®)
- [Brigatinib (Alunbrig®)](https://www.ncpe.ie/brigatinib-alunbrig/)
- [Bosutinib (Bosulif®)](https://www.ncpe.ie/bosutinib-bosulif/)
- [Bosentan (Tracleer®)](https://www.ncpe.ie/bosentan-tracleer/) - NCPE Pharmacoeconomic Evaluation Bosentan (Tracleer®)
- [Blinatumomab (Blincyto®) (paediatric ALL)](https://www.ncpe.ie/blinatumomab-blincyto-paediatric-all/)
- [Blinatumomab (Blincyto®)  CD19+ BCP-ALL](https://www.ncpe.ie/blinatumomab-blincyto-cd19-bcp-all/) - NCPE Pharmacoeconomic Evaluation Blinatumomab (Blincyto®) CD19+ BCP-ALL
- [Bilastine (Drynol®)](https://www.ncpe.ie/bilastine-drynol/) - NCPE Pharmacoeconomic Evaluation Bilastine (Drynol ®)
- [Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®)](https://www.ncpe.ie/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy/)
- [Bezlotoxumab (Zinplava®)](https://www.ncpe.ie/bezlotoxumab-zinplava/) - NCPE Pharmacoeconomic Evaluation Bezlotoxumab (Zinplava®)
- [Osimertinib (Tagrisso®)](https://www.ncpe.ie/osimertinib-tagrisso/) - NCPE Pharmacoeconomic Evaluation Osimertinib (Tagrisso®)
- [Pertuzumab  (Perjeta®) for Adjuvant HER2 positive breast cancer](https://www.ncpe.ie/pertuzumab-perjeta-for-her2-positive-breast-cancer/)
- [Perampanel (Fycompa®)](https://www.ncpe.ie/perampanel-fycompa/)
- [Pentosan Polysulfate Sodium [PPS] (Elmiron®)](https://www.ncpe.ie/pentosan-polysulfate-sodium-pps-elmiron/)
- [Osilodrostat (Isturisa®). HTA ID: 22023](https://www.ncpe.ie/osilodrostat-isturisa-hta-id-22023/)
- [Opium Tincture (Dropizol®)](https://www.ncpe.ie/opium-tincture-dropizol/)
- [Opicapone (Ongentys®). HTA ID: 20055](https://www.ncpe.ie/opicapone-ongentys-hta-id-20055/)
- [Onasemnogene abeparvovec (Zolgensma®). HTA ID: 20021](https://www.ncpe.ie/onasemnogene-abeparvovec-zolgensma-hta-id-20021/)
- [Pembrolizumab (Keytruda®) for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.](https://www.ncpe.ie/pembrolizumab-keytruda-for-the-treatment-of-unresectable-or-advanced-metastatic-melanoma-in-adults-refractory-to-ipilimumab/) - NCPE Pharmacoeconomic Evaluation Pembrolizumab (Keytruda®)
- [Pembrolizumab (Keytruda®) for the first line treatment of unresectable or advanced metastatic melanoma in adults.](https://www.ncpe.ie/pembrolizumab-keytruda/) - NCPE Pharmacoeconomic Evaluation Pembrolizumab (Keytruda®)
- [Omega-3-acid ethyl esters (Omacor®)](https://www.ncpe.ie/2955/)
- [Omalizumab (Xolair®) for the treatment of severe allergic asthma](https://www.ncpe.ie/omalizumab-xolair-for-the-treatment-of-severe-allergic-asthma/) - NCPE Pharmacoeconomic Evaluation Omalizumab (Xolair®)
- [Omalizumab (Xolair®)](https://www.ncpe.ie/omalizumab-xolair/)
- [Olaparib (Lynparza®) tablets for BRCA-mutated platinum sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer](https://www.ncpe.ie/olaparib-lynparza-tablets-for-brca-mutated-platinum-sensitive-relapsed-ovarian-fallopian-tube-or-primary-peritoneal-cancer/)
- [Olaparib (Lynparza®) for platinum sensitive relapsed ovarian cancer](https://www.ncpe.ie/olaparib-lynparza-for-platinum-sensitive-relapsed-ovarian-cancer/)
- [Pembrolizumab (Keytruda®) for NSCLC (second line)](https://www.ncpe.ie/pembrolizumab-keytruda-for-nsclc/) - NCPE Pharmacoeconomic Evaluation Pembrolizumab (Keytruda®) for NSCLC (second line)
- [Benralizumab (Fasenra®)](https://www.ncpe.ie/benralizumab-fasenra/) - NCPE Pharmacoeconomic Evaluation Benralizumab (Fasenra®)
- [Olaparib (Lynparza®) for breast cancer](https://www.ncpe.ie/olaparib-lynparza-for-breast-cancer/)
- [Pembrolizumab (Keytruda®) for NSCLC (first line)](https://www.ncpe.ie/pembrolizumab-keytruda-for-first-line-nsclc/) - NCPE Pharmacoeconomic Evaluation Pembrolizumab (Keytruda®)
- [Alectinib (Alecensa®)](https://www.ncpe.ie/alectinib-alecensa/) - Pharmacoeconomic evaluation of alectinib (Alecensa®) for the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with crizotinib.
- [Belimumab (Benlysta®)](https://www.ncpe.ie/belimumab-benlysta/) - NCPE Pharmacoeconomic Evaluation Belimumab (Benlysta®)
- [Olaparib (Lynparza®) capsules for BRCA-mutated platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer](https://www.ncpe.ie/olaparib-lynparza-2/) - NCPE Pharmacoeconomic Evaluation Olaparib (Lynparza®)
- [Olaparib (Lynparza®) (1L maintenance of BRCA-mutated advanced OVCA)](https://www.ncpe.ie/olaparib-lynparza-1l-maintenance-of-brca-mutated-advanced-ovca/)
- [Belatacept (Nulojix®)](https://www.ncpe.ie/belatacept-nulojix/) - NCPE Pharmacoeconomic Evaluation Belatacept (Nulojix®)
- [Bedaquiline (Sirturo®)](https://www.ncpe.ie/bedaquiline-sirturo/) - NCPE Pharmacoeconomic Evaluation Bedaquiline (Sirturo®)
- [Bazedoxifene (Conbriza®)](https://www.ncpe.ie/bazedoxifene-conbriza/) - NCPE Pharmacoeconomic Evaluation Bazedoxifene (Conbriza®)
- [Oladaterol (Striverdi®, Respimat®)](https://www.ncpe.ie/oladaterol-striverdi-respimat/) - NCPE Pharmacoeconomic Evaluation Oladaterol (Striverdi®, Respimat®)
- [Adalimumab (Humira®)](https://www.ncpe.ie/adalimumab-humira/)
- [Ofatumumab (Kesimpta®). HTA ID: 21008](https://www.ncpe.ie/ofatumumab-kesimpta-hta-id-21008/)
- [Baricitinib (Olumiant®) for moderate to severe atopic dermatitis. HTA ID: 20056](https://www.ncpe.ie/baricitinib-olumiant-for-moderate-to-severe-atopic-dermatitis-hta-id-20056/)
- [Ofatumumab (Arzerra®) (Refractory CLL)](https://www.ncpe.ie/ofatumumab-arzerra/) - NCPE Pharmacoeconomic Evaluation Ofatumumab (Arzerra®)
- [Baricitinib (Olumiant®) for atopic dermatitis. HTA ID: 21050](https://www.ncpe.ie/baricitinib-olumiant-for-atopic-dermatitis-hta-id-21050/)
- [Ofatumumab (Arzerra®) (Previously untreated Chronic Lymphocytic Leukaemia)](https://www.ncpe.ie/ofatumumab-arzerra-previously-untreated-chronic-lymphocytic-leukaemia/)
- [Ocriplasmin (Jetrea®)](https://www.ncpe.ie/ocriplasmin-jetrea/) - NCPE Pharmacoeconomic Evaluation Ocriplasmin (Jetrea®)
- [Ocrelizumab (Ocrevus®) for RMS](https://www.ncpe.ie/ocrelizumab-ocrevus-for-rms/) - NCPE Pharmacoeconomic Evaluation Ocrelizumab (Ocrevus®)
- [Ocrelizumab (Ocrevus®) for PPMS](https://www.ncpe.ie/ocrelizumab-ocrevus-for-ppms/) - NCPE Pharmacoeconomic Evaluation Ocrelizumab (Ocrevus®)
- [Obinutuzumab (Gazyvaro®) for previously untreated advanced follicular lymphoma](https://www.ncpe.ie/obinutuzumab-gazyvaro-for-previously-untreated-advanced-follicular-lymphoma/)
- [Obinutuzumab (Gazyvaro®) for Lymphocytic Leukaemia](https://www.ncpe.ie/obinutuzumab-gazyvaro/) - NCPE Pharmacoeconomic Evaluation Obinutuzumab (Gazyvaro®)
- [Obinutuzumab (Gazyvaro®) for Follicular Lymphoma](https://www.ncpe.ie/obinutuzumab-gazyvaro-for-follicular-lymphoma/) - NCPE Pharmacoeconomic Evaluation Obinutuzumab (Gazyvaro®)
- [Nusinersin (Spinraza®)](https://www.ncpe.ie/nusinersin-spinraza/) - Pharmacoeconomic Evaluation of Nusinersin (Spinraza®) for the treatment of 5q spinal muscular atrophy (SMA)
- [Nomegestrol acetate/estradiol (Zoely®)](https://www.ncpe.ie/nomace2-zoely/) - NCPE Pharmacoeconomic Evaluation Nomac/E2 (Zoely®)
- [Nivolumab plus ipilimumab (Opdivo® plus Yervoy®)](https://www.ncpe.ie/nivolumab-plus-ipilimumab-opdivio-plus-yervoy/) - NCPE Pharmacoeconomic Evaluation Nivolumab plus ipilimumab (Opdivio® plus Yervoy®)
- [Dulaglutide (Trulicity®)](https://www.ncpe.ie/dulaglutide-trulicity/) - NCPE Pharmacoeconomic Evaluation Dulaglutide (Trulicity®)
- [Dronedarone (Multaq®)](https://www.ncpe.ie/dronedarone-multaq/) - NCPE Pharmacoeconomic Evaluation Dronedarone (Multaq®)
- [Doxylamine/Pyridoxine (Xonvea®)](https://www.ncpe.ie/doxylamine-pyridoxine-xonvea/)
- [Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate  (Delstrigo®)](https://www.ncpe.ie/doravirine-lamivudine-tenofovir-disoproxil-fumarate-delstrigo/)
- [Doravirine (Pifeltro®)](https://www.ncpe.ie/doravirine-pifeltro/)
- [Dolutegravir/Rilpivirine (Juluca®)](https://www.ncpe.ie/dolutegravir-rilpivirine-juluca/)
- [Lutetium (177Lu) Oxodotreotide (Lutathera®)](https://www.ncpe.ie/lutetium-177lu-oxodotreotide-lutathera/)
- [Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®)](https://www.ncpe.ie/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy/) - NCPE Pharmacoeconomic Evaluation Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®
- [Nivolumab (Opdivo®) for urothelial carcinoma](https://www.ncpe.ie/nivolumab-opdivo-for-urothelial-carcinoma/)
- [Nivolumab (Opdivo®) for NSCLC](https://www.ncpe.ie/nivolumab-opdivio-for-nsclc/) - NCPE Pharmacoeconomic Evaluation Nivolumab (Opdivio®)
- [Loxapine inhalation powder (Adasuve®)](https://www.ncpe.ie/loxapine-inhalation-powder-adasuve/) - NCPE Pharmacoeconomic Evaluation Loxapine inhalation powder (Adasuve®)
- [Lotemax 0.5% eye drops suspension (Loteprednol)](https://www.ncpe.ie/lotemax-0-5-eye-drops-suspension-loteprednol/) - NCPE Pharmacoeconomic Evaluation Lotemax 0.5% eye drops suspension (Loteprednol)
- [Nivolumab (Opdivo®) for non-squamous NSCLC](https://www.ncpe.ie/nivolumab-opdivio-for-non-squamous-nsclc/) - NCPE Pharmacoeconomic Evaluation Nivolumab (Opdivo®) for non-squamous NSCLC
- [Lornoxicam (Xefo®)](https://www.ncpe.ie/lornoxicam-xefo/) - NCPE Pharmacoeconomic Evaluation Lornoxicam (Xefo®)
- [Lorlatinib (Lorviqua®)](https://www.ncpe.ie/lorlatinib-lorviqua/)
- [Nivolumab (Opdivo®) for Melanoma](https://www.ncpe.ie/nivolumab-opdivio-for-melanoma/) - NCPE Pharmacoeconomic Evaluation Nivolumab (Opdivio®)
- [Nivolumab (Opdivo®) for head and neck cancer](https://www.ncpe.ie/nivolumab-opdivo-for-head-and-neck-cancer/) - NCPE Pharmacoeconomic Evaluation Nivolumab (Opdivo®)
- [Nivolumab (Opdivo®) for classical Hodgkin Lymphoma](https://www.ncpe.ie/nivolumab-opdivo-for-classical-hodgkin-lymphoma/) - NCPE Pharmacoeconomic Evaluation Nivolumab (Opdivo®)
- [Lomitapide (Lojuxta®)](https://www.ncpe.ie/lomitapide-lojuxta/) - NCPE Pharmacoeconomic Evaluation Lomitapide (Lojuxta®)
- [Lisdexamfetamine dimesylate (Tyvense®)](https://www.ncpe.ie/lisdexamfetamine-dimesylate-tyvense/) - Lisdexamfetamine dimesylate (Tyvense®) for Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.
- [Nivolumab (Opdivo®) for advanced renal cell carcinoma](https://www.ncpe.ie/nivolumab-opdivo-for-advanced-renal-cell-carcinoma/)
- [Liraglutide (Victoza®)](https://www.ncpe.ie/liraglutide-victoza/) - NCPE Rapid Review of Liraglutide (Victoza®)
- [Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of adults with melanoma](https://www.ncpe.ie/nivolumab-opdivo-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-melanoma/)
- [Liquid Paraffin Ointment (VitA-POS Opthalmic®)](https://www.ncpe.ie/liquid-paraffin-ointment-vita-pos-opthalmic/) - NCPE Pharmacoeconomic Evaluation Liquid Paraffin Ointment (VitA-POS Opthalmic®)
- [Liposomal daunorubicin and cytarabine (Vyxeos Liposomal®)](https://www.ncpe.ie/liposomal-daunorubicin-and-cytarabine-cpx-351vyxeos/)
- [Niraparib (Zejula®) for recurrent OVCA maintenance treatment](https://www.ncpe.ie/niraparib-zejula/)
- [Lipegfilgrastim (Lonquex®)](https://www.ncpe.ie/lipegfilgrastim-lonquex/) - NCPE Pharmacoeconomic Evaluation Lipegfilgrastim (Lonquex®)
- [Linagliptin (Trajenta®)](https://www.ncpe.ie/linagliptin-trajenta/) - NCPE Pharmacoeconomic Evaluation Linagliptin (Trajenta®)
- [Linaclotide (Constella®)](https://www.ncpe.ie/linaclotide-clonstella/) - NCPE Pharmacoeconomic Evaluation Linaclotide (Clonstella®)
- [Lidocaine 5% plasters (Versatis®)](https://www.ncpe.ie/lidocaine-5-plasters-versatis/) - NCPE Pharmacoeconomic Evaluation Lidocaine 5% plasters (Versatis®)
- [Nintedanib (Vargatef®)](https://www.ncpe.ie/nintedanib-vargatef/) - NCPE Pharmacoeconomic Evaluation Nintedanib (Vargatef®)
- [Levonorgestrel intrauterine system LNG-IUS (Jaydess®)](https://www.ncpe.ie/levonorgestrel-intrauterine-system-lng-ius-jaydess/)
- [Levonorgestrel Intrauterine System (Levosert®)](https://www.ncpe.ie/levonorgestrel-intrauterine-system-levosert/)
- [Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena®)](https://www.ncpe.ie/levonorgestrel-intrauterine-delivery-system-lng-ius-12-kyleena/) - NCPE Pharmacoeconomic Evaluation Levonorgestrel (Kyleena®)
- [Levofloxacin (Quinsair®)](https://www.ncpe.ie/levofloxacin-quinsair/) - NCPE Pharmacoeconomic Evaluation Levofloxacin (Quinsair®)
- [Dolutegravir/Lamivudine (Dovato®)](https://www.ncpe.ie/dolutegravir-lamivudine-dovato/)
- [Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa®)](https://www.ncpe.ie/levodopa-20mgml-carbidopa-monohydrate-5mg-intestinal-gel-duodopa/)
- [Letermovir (Prevymis®)](https://www.ncpe.ie/letermovir-prevymis/) - NCPE Pharmacoeconomic Evaluation Letermovir (Prevymis®)
- [Ambrisentan (Volibris®)](https://www.ncpe.ie/ambrisentan-volibris/) - NCPE Pharmacoeconomic Evaluation Ambrisentan (Volibris®)
- [Lesinurad (Zurampic®)](https://www.ncpe.ie/lesinurad-zurampic/) - NCPE Pharmacoeconomic Evaluation Lesinurad (Zurampic®)
- [Lenvatinib (Lenvima®) for HCC](https://www.ncpe.ie/lenvatinib-lenvima-2/)
- [Lenvatinib (Lenvima®)](https://www.ncpe.ie/lenvatinib-lenvima/)
- [Lenvatinib (Kisplyx®). HTA ID: 22057](https://www.ncpe.ie/lenvatinib-kisplyx-hta-id-22057/)
- [Lenvatinib (Kisplyx®)](https://www.ncpe.ie/lenvatinib-kisplyx/) - NCPE Pharmacoeconomic Evaluation Lenvatinib (Kisplyx®)
- [Lenalidomide (Revlimid®)](https://www.ncpe.ie/lenalidomide-revlimid/)
- [Ledipasvir/sofosbuvir (Harvoni®)](https://www.ncpe.ie/ledipasvirsofosbuvir-harvoni/) - Pharmacoeconomic Evaluation of Ledipasvir/sofosbuvir (Harvoni®)
- [Nintedanib (Ofev®)](https://www.ncpe.ie/nintedanib-ofev/) - NCPE Pharmacoeconomic Evaluation Nintedanib (Ofev®)
- [Nilotinib (Tasigna®) newly diagnosed CML](https://www.ncpe.ie/nilotinib-tasigna-newly-diagnosed-cml/) - NCPE Pharmacoeconomic Evaluation Nilotinib (Tasigna®) for newly diagnosed CML
- [Lapatinib (Tyverb®)](https://www.ncpe.ie/lapatinib-tyverb/) - NCPE Pharmacoeconomic Evaluation Lapatinib (Tyverb®)
- [Lanadelumab (Takhzyro®)](https://www.ncpe.ie/lanadelumab-takhzyro/)
- [Nilotinib (Tasigna®) CML resistant/intolerant to imatinib](https://www.ncpe.ie/nilotinib-tasigna/) - NCPE Pharmacoeconomic Evaluation Nilotinib (Tasigna®)
- [Dolutegravir (Tivicay®)](https://www.ncpe.ie/dolutegravir-tivicay/) - NCPE Pharmacoeconomic Evaluation Dolutegravir (Tivicay®)
- [Lacosamide (Vimpat ®)](https://www.ncpe.ie/lacosamide-vimpat/)
- [Netupitant/palonosetron (Akynzeo®)](https://www.ncpe.ie/netupitantpalonosetron-akynzeo/) - NCPE Pharmacoeconomic Evaluation Netupitant/palonosetron (Akynzeo®)
- [Ixekizumab (Taltz®) for psoriatic arthritis](https://www.ncpe.ie/ixekizumab-taltz-for-psoriatic-arthritis/)
- [Nepafenac (Nevanac®)](https://www.ncpe.ie/nepafenac-nevanac-2/) - NCPE Pharmacoeconomic Evaluation Nepafenac (Nevanac®)
- [Ixekizumab (Taltz®)](https://www.ncpe.ie/ixekizumab-taltz/) - NCPE Pharmacoeconomic Evaluation Ixekizumab (Taltz®)
- [Natalizumab (Tysabri®)](https://www.ncpe.ie/natalizumab-tysabri/) - NCPE Pharmacoeconomic Evaluation Natalizumab (Tysabri®)
- [Ixazomib (Ninlaro®)](https://www.ncpe.ie/ixazomib-ninlaro/) - NCPE Pharmacoeconomic Evaluation Ixazomib (Ninlaro®)
- [Dienogest (Visanne®)](https://www.ncpe.ie/dienogest-visanne/) - NCPE Pharmacoeconomic Evaluation Dienogest (Visanne®)
- [Diclofenac (Itami®)](https://www.ncpe.ie/diclofenac-itami/)
- [Dexmedetomidine (Dexdor®)](https://www.ncpe.ie/dexmedetomidine-dexdor/) - NCPE Pharmacoeconomic Evaluation Dexmedetomidine (Dexdor®)
- [Ivacaftor (Kalydeco®) for the treatment of CF patients with the R117H mutation.](https://www.ncpe.ie/ivacaftor-kalydeco-for-the-treatment-of-cf-patients-with-the-r117h-mutation/) - NCPE Pharmacoeconomic Evaluation Ivacaftor (Kalydeco®)
- [Ivacaftor (Kalydeco®) for patients with CF 2 years +](https://www.ncpe.ie/ivacaftor-kalydeco-for-patients-with-cf-2-years/) - NCPE Pharmacoeconomic Evaluation Ivacaftor (Kalydeco®)
- [Ivacaftor (Kalydeco®)](https://www.ncpe.ie/ivacaftor-kaldeco/) - NCPE Pharmacoeconomic Evaluation Ivacaftor (Kalydeco®)
- [IUB™ Ballerine® MIDI 15mm diameter SCU300B. HTA ID: 20062](https://www.ncpe.ie/iub-ballerine-midi-15mm-diameter-scu300b-hta-id-20062/)
- [IUB™ Ballerine® MIDI 15mm diameter SCU300B. HTA ID: 20027](https://www.ncpe.ie/iub-ballerine-midi-15mm-diameter-scu300b-hta-id-20027/)
- [Isavuconazole (Cresemba®) for the treatment of mucormycosis](https://www.ncpe.ie/isavuconazole-cresemba-for-the-treatment-of-mucormycosis/) - NCPE Pharmacoeconomic Evaluation Isavuconazole (Cresemba®) for the treatment of mucormycosis.
- [Isavuconazole (Cresemba®) for the treatment of invasive aspergillosis.](https://www.ncpe.ie/isavuconazole-cresemba-for-the-treatment-of-invasive-aspergillosis/) - NCPE Pharmacoeconomic Evaluation Isavuconazole (Cresemba®) for the treatment of invasive aspergillosis.
- [Iron isomaltoside 1000 (MonoVer®)](https://www.ncpe.ie/iron-isomaltoside-1000-monover/) - NCPE Pharmacoeconomic Evaluation Iron isomaltoside 1000 (MonoVer®)
- [Iron (III) isomaltoside 1000 (Monover®)](https://www.ncpe.ie/iron-iii-isomaltoside-1000-monover/) - NCPE Pharmacoeconomic Evaluation Iron (III) isomaltoside 1000 (Monover®)
- [Iron (III) isomaltoside 1000 (Diafer®)](https://www.ncpe.ie/iron-iii-isomaltoside-1000-diafer/) - NCPE Pharmacoeconomic Evaluation Iron (III) isomaltoside 1000 (Diafer®)
- [Ipilimumab (Yervoy®)](https://www.ncpe.ie/ipilimumab-yervoy/)
- [Naltrexone / bupropion (Mysimba®)](https://www.ncpe.ie/naltrexone-bupropion-mysimba/) - NCPE Pharmacoeconomic Evaluation Naltrexone / bupropion (Mysimba®)
- [Insulin Glargine U300 (Toujeo®)](https://www.ncpe.ie/insulin-glargine-u300-toujeo/) - NCPE Pharmacoeconomic Evaluation Insulin Glargine U300 (Toujeo®)
- [Insulin Glargine (Abasaglar®)](https://www.ncpe.ie/insulin-glargine-abasaglar/) - NCPE Pharmacoeconomic Evaluation Insulin Glargine (Abasaglar®)
- [Insulin degludec/liraglutide (IDegLira) (Xultophy®)](https://www.ncpe.ie/insulin-degludecliraglutide-ideglira-xultophy/) - NCPE Pharmacoeconomic Evaluation Insulin degludec/liraglutide (IDegLira) (Xultophy®)
- [Naloxegel (Moventig®)](https://www.ncpe.ie/naloxegel-moventig/)
- [Nalmefene (Selincro®)](https://www.ncpe.ie/nalmefene-selincro/) - NCPE Pharmacoeconomic Evaluation Nalmefene (Selincro®)
- [Glecaprevir/Pibrentasvir (Maviret®)](https://www.ncpe.ie/glecaprevirpibrentasvir-maviret/) - NCPE Pharmacoeconomic Evaluation Glecaprevir/Pibrentasvir (Maviret®)
- [Nab-paclitaxel (Abraxane®)](https://www.ncpe.ie/nab-paclitaxel-abraxane/) - NCPE Pharmacoeconomic Evaluation Nab-paclitaxel (Abraxane®)
- [Glasdegib (Daurismo®) in combination with low-dose cytarabine. HTA ID: 20041](https://www.ncpe.ie/glasdegib-daurismo-in-combination-with-low-dose-cytarabine-hta-id-20041/)
- [Gemtuzumab ozogamicin (Mylotarg®)](https://www.ncpe.ie/gemtuzumab-ozogamicin-mylotarg/)
- [Gefitinib (Iressa®)](https://www.ncpe.ie/gefitinib-iressa/) - NCPE Pharmacoeconomic Evaluation Gefitinib (Iressa®)
- [Insulin Degludec (Tresiba®)](https://www.ncpe.ie/insulin-degludec-tresiba/) - NCPE Pharmacoeconomic Evaluation Insulin Degludec (Tresiba®)
- [Insulin aspart (NovoRapid® FlexTouch ®)](https://www.ncpe.ie/insulin-aspart-novorapid-flextouch/) - Pharmacoeconomic Evaluation of Insulin aspart (NovoRapid® FlexTouch ®)
- [Fremanezumab (Ajovy®)](https://www.ncpe.ie/fremanezumab-ajovy/)
- [Mirabegron (Betmiga®)](https://www.ncpe.ie/mirabegron-betmiga/)
- [Migalastat (Galafold®)](https://www.ncpe.ie/migalastat-galafold/) - NCPE Pharmacoeconomic Evaluation Migalastat (Galafold®)
- [Fluticasone furoate/vilanterol (Relvar™ Ellipta™)](https://www.ncpe.ie/fluticasone-furoatevilanterol-relvar-ellipta/)
- [Fluticasone furoate/ umeclidinium/ vilantero (Trelegy™ Ellipta™)](https://www.ncpe.ie/fluticasone-furoate-umeclidinium-vilantero-trelegy-ellipta/)
- [Mifamurtide (Mepact®)](https://www.ncpe.ie/mifamurtide-mepact/) - NCPE Pharmacoeconomic Evaluation Mifamurtide Mepact®
- [Midostaurin (Rydapt®) for ASM](https://www.ncpe.ie/midostaurin-rydapt-for-asm/) - NCPE Pharmacoeconomic Evaluation Midostaurin (Rydapt®) for ASM
- [Midostaurin (Rydapt®) for AML](https://www.ncpe.ie/midostaurin-rydapt-for-aml/) - NCPE Pharmacoeconomic Evaluation Midostaurin (Rydapt®)
- [Methoxyflurane (Penthrox®)](https://www.ncpe.ie/methoxyflurane-penthrox/) - NCPE Pharmacoeconomic Evaluation Methoxyflurane (Penthrox®)
- [Insulin aspart (Fiasp®)](https://www.ncpe.ie/insulin-aspart-fiasp/) - NCPE Pharmacoeconomic Evaluation Insulin aspart (Fiasp®)
- [Inotuzumab ozogamicin (Besponsa®)](https://www.ncpe.ie/inotuzumab-ozogamicin-besponsa/) - NCPE Pharmacoeconomic Evaluation Inotuzumab ozogamicin (Besponsa®)
- [Inotersen (Tegsedi®). HTA ID: 19034](https://www.ncpe.ie/inotersen-tegsedi/)
- [Inhaled insulin (Exubera®)](https://www.ncpe.ie/ncpe-inhaled-insulin-exubera-assessment/) - NCPE Pharmacoeconomic Evaluation of Inhaled Insulin (Exubera®)
- [Ingenol mebutate gel (Picato®)](https://www.ncpe.ie/ingenol-mebutate-gel-picato/)
- [Infliximab (Remsima® SC). HTA ID: 20042](https://www.ncpe.ie/infliximab-remsima-subcutaneous-hta-id-20042/)
- [Infliximab (Remsima SC®). HTA ID: 20012](https://www.ncpe.ie/infliximab-remsima-sc-hta-id-20012/)
- [Infliximab (Inflectra®)](https://www.ncpe.ie/infliximab-inflectra/) - NCPE Pharmacoeconomic Evaluation Infliximab (Inflectra®)
- [Mepolizumab (Nucala®) 100mg solution in pre-filled pen and syringe](https://www.ncpe.ie/mepolizumab-nucala-for-severe-refractory-eosinophilic-asthma/)
- [Mepolizumab (Nucala®) 100mg powder for solution for injection](https://www.ncpe.ie/mepolizumab-nucala/)
- [Melatonin (Circadin®)](https://www.ncpe.ie/melatonin-circadin/) - NCPE Pharmacoeconomic Evaluation Melatonin (Circadin®)
- [Mannitol Dry Powder (Bronchitol®)](https://www.ncpe.ie/bronchitol/)
- [Magnesium Aspartate Dihydrate (Magnaspartate®)](https://www.ncpe.ie/magnesium-aspartate-dihydrate-magnaspartate/)
- [Macitentan (Opsumit®)](https://www.ncpe.ie/macitentan-opsumit/) - NCPE Pharmacoeconomic Evaluation Macitentan(Opsumit®)
- [Azilsartan (Edarbi®)](https://www.ncpe.ie/azilsartan-edarbi/) - NCPE Pharmacoeconomic Evaluation Azilsartan (Edarbi®)
- [Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista®)](https://www.ncpe.ie/azelastine-hydrochloride-and-fluticasone-propionate-nasal-spray-dymista/) - Pharmacoeconomic evaluation of Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista®) for the Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
- [Axitinib (Inlyta®)](https://www.ncpe.ie/axitinib-inlyta/) - NCPE Pharmacoeconomic Evaluation Axitinib (Inlyta®)
- [Indacterol/glycopyrronium/mometasone furoate (Enerzair®). HTA ID: 20023](https://www.ncpe.ie/indacterol-glycopyrronium-mometasone-furoate-enerzair-hta-id-20023/)
- [Indacaterol (Onbrez®)](https://www.ncpe.ie/indacaterol-onbrez/) - NCPE Pharmacoeconomic Evaluation Indacaterol (Onbrez®)
- [Incobotulinum Toxin Type A (Xeomin®)](https://www.ncpe.ie/incobotulinum-toxin-type-a-xeomin/) - NCPE Pharmacoeconomic Evaluation Incobotulinum Toxin Type A (Xeomin®)
- [Imiquimod 3.75% (Zyclara®)](https://www.ncpe.ie/imiquimod-zyclara/) - NCPE Pharmacoeconomic Evaluation Imiquimod (Zyclara®
- [Imipenem/cilastatin/relebactam (Recarbrio®). HTA ID: 20040](https://www.ncpe.ie/imipenem-cilastatin-relebactam-recarbrio-hta-id-20040/)
- [Idelalisib (Zydelig®)](https://www.ncpe.ie/idelalisib-zydelig/) - NCPE Pharmacoeconomic Evaluation Idelalisib (Zydelig®)
- [Idebenone (Raxone®)](https://www.ncpe.ie/idebenone-raxone/) - NCPE Pharmacoeconomic Evaluation Idebenone (Raxone®)
- [Idarucizumab (Praxbind®)](https://www.ncpe.ie/idarucizumab-praxbind/) - NCPE Pharmacoeconomic Evaluation Idarucizumab (Praxbind®)
- [Icatibant (Firazyr®)](https://www.ncpe.ie/icatibant-firazyr/)
- [Ibrutinib (Imbruvica®) for previously untreated CLL](https://www.ncpe.ie/ibrutinib-imbruivca-for-previously-untreated-cll/) - NCPE Pharmacoeconomic Evaluation Ibrutinib (Imbruvica®) for previously untreated CLL
- [Ibrutinib (Imbruvica®) for MCL](https://www.ncpe.ie/ibrutinib-imbruvica-for-mcl/)
- [Fluocinolone acetonide intravitreal implant (Iluvien®) for non-infectious uveitis. HTA ID: 20050](https://www.ncpe.ie/fluocinolone-acetonide-intravitreal-implant-iluvien-hta-id-20050/)
- [Ferumoxytol (Rienso®)](https://www.ncpe.ie/ferumoxytol-rienso/)
- [Ferric maltol (Feraccru®)](https://www.ncpe.ie/ferric-maltol-feraccru_/) - NCPE Pharmacoeconomic Evaluation Ferric Maltol (Feraccru®)
- [Ibrutinib (Imbruvica®) for CLL](https://www.ncpe.ie/ibrutinib-imbruvica-for-cll/)
- [Fampridine (Fampyra®)](https://www.ncpe.ie/fampridine-fampyra/) - NCPE Pharmacoeconomic Evaluation Fampridine (Fampyra®)
- [Avanafil (Spedra®)](https://www.ncpe.ie/avanafil-spedra/) - NCPE Pharmacoeconomic Evaluation Avanafil (Spedra®)
- [Fluoride toothpaste (Duraphat® 5,000 ppm)](https://www.ncpe.ie/fluoride-toothpaste-duraphat-5000-ppm/)
- [Atezolizumab (Tecentriq® ) for Urothelial Carcinoma 2L](https://www.ncpe.ie/atezolizumab-tecentriq-for-urothelial-carcinoma-2l/)
- [Aspirin 81mg/Esomeprazole 20mg (Axanum®)](https://www.ncpe.ie/axanum-aspirin-81mgesomeprazole-20mg/) - NCPE Pharmacoeconomic Evaluation Axanum®
- [Asenapine (Sycrest®)](https://www.ncpe.ie/asenapine-sycrest/) - NCPE Pharmacoeconomic Evaluation Asenapine (Sycrest®)
- [Aripiprazole (Abilify Maintena®)](https://www.ncpe.ie/aripiprazole-abilify-maintena/)
- [Apixaban (Eliquis®)](https://www.ncpe.ie/apixaban-eliquis-for-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe-in-adults/)
- [Degarelix (Firmagon®)](https://www.ncpe.ie/degarelix-firmagon/) - NCPE Rapid Review of Degarelix (Firmagon®)
- [Defibrotide (Defitelio®)](https://www.ncpe.ie/defibrotide-defitelio/) - NCPE Defibrotide (Defitelio®) Health Technology Assessment
- [Decitabine (Dacogen®)](https://www.ncpe.ie/decitabine-dacogen/) - NCPE Pharmacoeconomic Evaluation Decitabine (Dacogen®)
- [Fluocinolone acetonide intravitreal implant (Iluvien®) for diabetic macular oedema](https://www.ncpe.ie/fluocinolone-acetonide-iluvien/) - NCPE Pharmacoeconomic Evaluation Fluocinolone acetonide (Iluvien®)
- [Fingolimod (Gilenya®)](https://www.ncpe.ie/fingolimod-gilenya-4/) - NCPE Pharmacoeconomic Evaluation Fingolimod (Gilenya®)
- [Filgotinib (Jyseleca®). HTA ID: 20047](https://www.ncpe.ie/filgotinib-jyseleca-hta-id-20047/)
- [Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza®)](https://www.ncpe.ie/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza/) - NCPE Pharmacoeconomic Evaluation Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza®)
- [Darunavir & cobicistat (Rezolsta®)](https://www.ncpe.ie/darunavir-cobicistat-rezolsta/) - NCPE Pharmacoeconomic Evaluation Darunavir & cobicistat (Rezolsta®)
- [Amsacrine (Amsidine®)](https://www.ncpe.ie/amsacrine-amsidine/) - NCPE Pharmacoeconomic Evaluation Amsacrine (Amsidine®)
- [Daratumumab (Darzalex®) in combination with lenalidomide and dexamethasone](https://www.ncpe.ie/daratumumab-darzalex-in-combination-with-lenalidomide-and-dexamethasone/)
- [Amifampridine (Firdapse®)](https://www.ncpe.ie/amifampridine-firdapse/) - NCPE Pharmacoeconomic Evaluation Amifampridine (Firdapse®)
- [Alogliptin (Vipidia®)](https://www.ncpe.ie/alogliptin-vipidia/) - NCPE Pharmacoeconomic Evaluation Alogliptin (Vipidia®)
- [Dalbavancin (Xydalba®)](https://www.ncpe.ie/dalbavancin-xydalba/) - NCPE Pharmacoeconomic Evaluation Dalbavancin (Xydalba ®).
- [Dacomitinib (Vizimpro®)](https://www.ncpe.ie/dacomitinib-vizimpro/)
- [Daclizumab (Zinbryta®)](https://www.ncpe.ie/daclizumab-zinbryta/) - NCPE Pharmacoeconomic Evaluation Daclizumab (Zinbryta®)
- [Aflibercept (Eylea®)](https://www.ncpe.ie/aflibercept-eylea/) - NCPE Pharmacoeconomic Evaluation Aflibercept (Eylea®)
- [Afatinib (Giotrif®)](https://www.ncpe.ie/afatinib-giotrif/) - NCPE Pharmacoeconomic Evaluation Afatinib (Giotrif®)
- [Adenuric (Febuxostat®)](https://www.ncpe.ie/adenuric-febuxostat/) - NCPE Rapid Review of Adenuric (Febuxostat®)
- [Aclidinium bromide / formoterol fumarate dihydrate (Brimica®  Genuair®)](https://www.ncpe.ie/aclidinium-bromide-formoterol-fumarate-dihydrate-brimica-genuair/) - NCPE Pharmacoeconomic Evaluation Aclidinium bromide / formoterol fumarate dihydrate (Brimica® Genuair®)
- [Aclidinium bromide (Eklira Genuair®)](https://www.ncpe.ie/aclidinium-bromide-eklira-genuair/) - NCPE Pharmacoeconomic Evaluation Aclidinium bromide (Eklira Genuair®)
- [Aceclofenac (Vitafen®)](https://www.ncpe.ie/aceclofenac-vitafen/) - NCPE Pharmacoeconomic Evaluation Aceclofenac (Vitafen®)
- [Abiraterone acetate (Zytiga®) for mHSPC](https://www.ncpe.ie/abiraterone-acetate-zytiga-for-mhspc/)
- [Meningitis B Vaccine – February 2014](https://www.ncpe.ie/meningitis-b-vaccine-february-2014-2/)
- [Human Papillomavirus Vaccine](https://www.ncpe.ie/human-papillomavirus-vaccine-2/)
- [Rotavirus Vaccine](https://www.ncpe.ie/rotavirus-vaccine/) - NCPE Pharmacoeconomic Evaluation Rotavirus Vaccine
- [Colorectal Cancer Screening programme](https://www.ncpe.ie/colectoral-cancer-screening-programme/) - NCPE Rapid Review of Colectoral Cancer Screening Programme
- [Oncotype DX®](https://www.ncpe.ie/oncotype-dx/) - NCPE Pharmacoeconomic Evaluation Oncotype DX®
- [Colorectal Cancer Screening programme](https://www.ncpe.ie/colorectal-cancer-screening-programme/)
- [Vacancies](https://www.ncpe.ie/vacancies/)
- [Update on Pharmacoeconomics in the Irish Healthcare Setting 2022](https://www.ncpe.ie/update-on-pharmacoeconomics-in-the-irish-healthcare-setting-2022/)
- [COVID-19 Evidence Review Group](https://www.ncpe.ie/latest-updates-from-the-covid-19-evidence-review-group-for-medicines/) - COVID-19 Evidence Review Group for Medicines
- [Press Release HAG EUNETHTA21](https://www.ncpe.ie/press-release-hag-eunethta21/)
- [Covid updates](https://www.ncpe.ie/covid-updates/)
- [Ireland, as part of Beneluxa, extends its collaborative network.](https://www.ncpe.ie/ireland-as-part-of-beneluxa-extends-its-collaborative-network/)
- [Update on Pharmacoeconomics in the Irish Healthcare Setting 2020](https://www.ncpe.ie/update-on-pharmacoeconomics-in-the-irish-healthcare-setting-2020/)
- [Vacancies](https://www.ncpe.ie/vacancy-for-statistician-at-ncpe/)
- [Pre-submission meetings](https://www.ncpe.ie/pre-submission-meetings/)
- [Annual NCPE Course](https://www.ncpe.ie/save-the-date/)
- [Tofacitinib (Xeljanz®)](https://www.ncpe.ie/tofacitinib-xeljanz/) - NCPE Pharmacoeconomic Evaluation Tofacitinib (Xeljanz®)
- [Patient Education Programme](https://www.ncpe.ie/patient-education-programme/)
- [Update on Pharmacoeconomics in the Irish Healthcare Setting 2016](https://www.ncpe.ie/update-on-pharmacoeconomics-in-the-irish-healthcare-setting-2016/)
- [Update in Pharmacoeconomics in the Irish Healthcare Setting March 2015](https://www.ncpe.ie/update-in-pharmacoeconomics-in-the-irish-healthcare-setting-march-2015/)
- [Lixisenatide (Lyxumia®)](https://www.ncpe.ie/lixisenatide-lyxumia/) - NCPE Pharmacoeconomic Evaluation Lixisenatide (Lyxumia®)
- [Update in Pharmacoeconomics 3/4th March 2014](https://www.ncpe.ie/update-in-pharmacoeconomics-34th-march-2014/)
- [TCD/NCPE Course on Evidence Synthesis](https://www.ncpe.ie/tcdncpe-course-on-evidence-synthesis/)
- [New Medicine Horizon Scanning Template](https://www.ncpe.ie/new-medicine-horizon-scanning/)
- [Cost-effectiveness acceptability frontier (CEAF)](https://www.ncpe.ie/cost-effectiveness-acceptability-frontier-ceaf/) - NCPE Glossary Cost-effectiveness acceptability frontier (CEAF)
- [Willingness-to-pay (WTP)](https://www.ncpe.ie/willingness-to-pay-wtp/) - NCPE Glossary Willingness-to-pay (WTP)
- [Universal Infant Hepatitis B Vaccination programme](https://www.ncpe.ie/universal-infant-hepatitis-b-vaccination-programme/) - NCPE Rapid Review of Universal Infant Hepatitis B Vaccine Programme
- [Utility](https://www.ncpe.ie/utility/) - NCPE Glossary Utility
- [Heterogeneity](https://www.ncpe.ie/ncpe-glossary-heterogeneity/) - NCPE Glossary Heterogeneity
- [Mapping](https://www.ncpe.ie/mapping/) - NCPE Glossary Mapping
- [Value-of-information (VOI)](https://www.ncpe.ie/value-of-information-voi/) - NCPE Glossary Value-of-information (VOI)
- [Uncertainty](https://www.ncpe.ie/uncertainty/) - NCPE Glossary Uncertainty
- [Transition Probability](https://www.ncpe.ie/transition-probability/) - NCPE Glossary Transition probability
- [Time Horizon](https://www.ncpe.ie/time-horizon/) - NCPE Glossary Time horizon
- [Technology](https://www.ncpe.ie/technology/) - NCPE Glossary Technology
- [Systematic review](https://www.ncpe.ie/systematic-review/) - NCPE Glossary Systematic reveiw
- [Statistical significance](https://www.ncpe.ie/statistical-significance/) - NCPE Glossary Statistical significance
- [Sensitivity analysis](https://www.ncpe.ie/sensitivity-analysis/) - NCPE Glossary Sensitivity analysis
- [Relative risk (RR)](https://www.ncpe.ie/relative-risk-rr/) - NCPE Glossary Relative risk (RR)
- [Quality-adjusted life year (QALY)](https://www.ncpe.ie/quality-adjusted-life-year-qaly/) - NCPE Glossary Quality-adjusted life year (QALY)
- [Productivity costs](https://www.ncpe.ie/productivity-costs/) - NCPE Glossary Productivity costs
- [Probability distribution](https://www.ncpe.ie/probability-distribution/) - NCPE Glossary Probability distribution
- [Probabilistic sensitivity analysis (PSA)](https://www.ncpe.ie/probabilistic-sensitivity-analysis-psa/) - NCPE Glossary Probabilistic sensitivity analysis (PSA)
- [Pharmacoeconomics](https://www.ncpe.ie/pharmacoeconomics/) - NCPE Glossary Pharmacoeconomics
- [Perspective](https://www.ncpe.ie/perspective/) - NCPE Glossary Perspective
- [Opportunity Cost ](https://www.ncpe.ie/opportunity-cost/) - NCPE Glossary Opportunity cost
- [Odds ratio (OR)](https://www.ncpe.ie/odds-ratio-or/) - NCPE Glossary Odds ratio (OR)
- [Net benefit](https://www.ncpe.ie/net-benefit/) - NCPE Glossary Net benefit
- [Micro-costing](https://www.ncpe.ie/micro-costing/) - NCPE Glossary Micro-costing
- [Meta-analyis](https://www.ncpe.ie/meta-analyis/) - NCPE Glossary Meta-analyis
- [Markov Model](https://www.ncpe.ie/markov-model/) - NCPE Glossary Markov model
- [Intangible costs](https://www.ncpe.ie/intangible-costs/) - NCPE Glossary Intangible costs
- [Indirect costs](https://www.ncpe.ie/indirect-costs/) - NCPE Glossary Indirect costs
- [Incremental cost effectiveness ratio (ICER)](https://www.ncpe.ie/incremental-cost-effectiveness-ratio-icer/) - NCPE Glossary Incremental cost effectiveness ratio (ICER)
- [Health-related quality of life (HRQoL, QOL)](https://www.ncpe.ie/health-related-quality-of-life-hrqol-qol/) - NCPE Glossary Health-related quality of life (HRQoL, QOL)
- [Health outomes](https://www.ncpe.ie/health-outomes/) - NCPE Glossary Health outomes
- [Health technology assessment (HTA)](https://www.ncpe.ie/health-technology-assessment-hta/) - NCPE Glossary Health technology assessment (HTA)
- [Extrapolation](https://www.ncpe.ie/extrapolation/) - NCPE Glossary Extrapolation
- [Extended dominance](https://www.ncpe.ie/extended-dominance/) - NCPE Glossary Extended dominance
- [EVPI](https://www.ncpe.ie/evpi/) - NCPE Glossary EVPI
- [Efficacy](https://www.ncpe.ie/efficacy/) - NCPE Glossary Efficacy
- [Economic evaluation](https://www.ncpe.ie/economic-evaluation/) - NCPE Glossary Economic evaluation
- [Economic model](https://www.ncpe.ie/economic-model/) - NCPE Glossary Economic model
- [Effectiveness](https://www.ncpe.ie/effectiveness/) - NCPE Glossary Effectiveness
- [Dominance](https://www.ncpe.ie/dominance/) - NCPE Glossary Dominance
- [Distribution](https://www.ncpe.ie/distribution/) - NCPE Glossary Distribution
- [Discounting](https://www.ncpe.ie/discounting/) - NCPE Glossary Discounting
- [Discount rate](https://www.ncpe.ie/discount-rate/) - NCPE Glossary Discount rate

## Pages

- [Home](https://www.ncpe.ie/) - The NCPE are an independent health technology assessment agency responsible for evaluating drug treatments for use in the Irish healthcare system.
- [About Us](https://www.ncpe.ie/about/)
- [Monthly Updates](https://www.ncpe.ie/monthly-updates/)
- [2026 Monthly Updates](https://www.ncpe.ie/2026-monthly-updates/)
- [Register for NCPE Events](https://www.ncpe.ie/ncpe-event-registration/)
- [Budget Impact Model Template](https://www.ncpe.ie/submission-process/submission-templates/budget-impact-model-template/)
- [HTA Guidelines](https://www.ncpe.ie/submission-process/hta-guidelines/) - Health Technology Assessment Guidelines detail the data required in a submission and the method for pharmacoeconomic analyses
- [Pre-submission meetings](https://www.ncpe.ie/submission-process/pre-submission-meetings/)
- [2025 Monthly Updates](https://www.ncpe.ie/monthly-updates/2025-monthly-updates/)
- [2025 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2025-peer-reviewed-publications/)
- [Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/)
- [2026 Peer-Reviewed Publications](https://www.ncpe.ie/2026-peer-review-publications/)
- [2027](https://www.ncpe.ie/2027-2/)
- [Education](https://www.ncpe.ie/education/)
- [Current Vacancies](https://www.ncpe.ie/vacancies/) - NCPE Vacancies
- [European Union HTA Regulation](https://www.ncpe.ie/international-collaborations/european-union-hta-regulation/)
- [Full HTA Submission Template](https://www.ncpe.ie/submission-process/submission-templates/format-of-full-submissions/)
- [Contact Us](https://www.ncpe.ie/contact-us/)
- [1999 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/1999-2/)
- [2000 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2000-2/)
- [2001 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2001-2/)
- [2002 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2002-2/)
- [2003 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2003-2/)
- [2004 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2004-2/)
- [2005 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2005-2/)
- [2006 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2006-2/)
- [2007 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2007-2/)
- [2008 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2008-2/)
- [2009 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2009-2/)
- [2010 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2010-2/)
- [2011 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2011-2/)
- [2012 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2012-2/)
- [2013 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2013-2/)
- [2014 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2014-2/)
- [2015 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2015-2/)
- [2016 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2016-2/)
- [2017 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2017-2/)
- [2018 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2018-2/)
- [2019 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2019-2/)
- [2020 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2020-2/)
- [2021 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2021-2/)
- [2022 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2022-2/)
- [2023 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2023-2/)
- [2024 Peer-Reviewed Publications](https://www.ncpe.ie/publications/peer-reviewed-publications/2024-2/)
- [Research](https://www.ncpe.ie/research/) - Research activities in the National Centre for Pharmacoeconomics
- [International Collaborations](https://www.ncpe.ie/international-collaborations/)
- [Other collaborations](https://www.ncpe.ie/international-collaborations/other-collaborations/)
- [Conference Abstracts](https://www.ncpe.ie/publications/conference-proceedings/)
- [For Patients](https://www.ncpe.ie/for-patients/) - The National Centre for Pharmacoeconomics provides education and training in pharmacoeconomics
- [Heads of Agency Group](https://www.ncpe.ie/international-collaborations/heads-of-agency-group/)
- [Template, Registration form, Guidelines and Tip Sheet](https://www.ncpe.ie/for-patients/template-guidelines-and-tip-sheet/) - NCPE contributes to both undergraduate and postgraduate education in a number of universities in Ireland
- [Beneluxa Initiative](https://www.ncpe.ie/international-collaborations/beneluxa-initiative/)
- [Rapid Review Template](https://www.ncpe.ie/submission-process/submission-templates/rapid-review-template/)
- [Covid 19 Evidence Reviews](https://www.ncpe.ie/research/covid-19-evidence-reviews/) - The COVID-19 Evidence Review Group for Medicines was established to support the HSE in managing the significant amount of information on treatments for COVID-19. This COVID-19 Evidence Review Group is comprised of evidence synthesis practitioners from across the National Centre for Pharmacoeconomics (NCPE), Medicines Management Programme (MMP) and the National Medicines Information Centre (NMIC). The group respond to queries raised via the Office of the Chief Clinical Officer, National Clinical Programmes and the Department of Health and respond in a timely way with the evidence review supporting the query.
- [Process Flowchart](https://www.ncpe.ie/submission-process/process-flochart/)
- [NCPE Recommendations](https://www.ncpe.ie/ncpe-recommendations/)
- [Interpreting NCPE Recommendations](https://www.ncpe.ie/interpreting-ncpe-recommendations/)
- [New Medicine Horizon Scanning](https://www.ncpe.ie/submission-process/submission-of-new-medicine-horizon-scan-by-manufacturers/)
- [Submission Templates](https://www.ncpe.ie/submission-process/submission-templates/)
- [Cookies Policy](https://www.ncpe.ie/cookies-statement/)
- [Glossary of Terms](https://www.ncpe.ie/for-patients/glossary-of-terms/)
- [Terms & Conditions](https://www.ncpe.ie/terms-conditions/)
- [Privacy Policy](https://www.ncpe.ie/privacy-policy/)
- [International Horizon Scanning Initiative](https://www.ncpe.ie/international-collaborations/international-horizon-scanning-initiative/)
- [EUnetHTA21](https://www.ncpe.ie/international-collaborations/european-union-hta-regulation/eunethta21/)
- [Overview of the Drug Reimbursement Process](https://www.ncpe.ie/submission-process/overview-of-the-drug-reimbursement-process/)
- [Submission Process](https://www.ncpe.ie/submission-process/) - The NCPE consider the cost effectiveness of all new medicines following receipt of an application for reimbursement under the Community Drugs Schemes.
- [Research & Education](https://www.ncpe.ie/research-education/)
- [Patients & Healthcare Professionals](https://www.ncpe.ie/patients-healthcare-professionals/)
- [Who We Are](https://www.ncpe.ie/who-we-are/)
- [Research Themes](https://www.ncpe.ie/research-themes/)
- [Healthcare Professionals](https://www.ncpe.ie/healthcare-professionals/)
- [Patient Submission Process Overview](https://www.ncpe.ie/for-patients/patient-submission-process-overview/) - The NCPE periodically holds courses on topics related to Pharmacoeconomics in Ireland.
- [Test Page](https://www.ncpe.ie/test-page/)
- [Other Technologies](https://www.ncpe.ie/other-technologies/)
- [Pharmacoeconomic Evaluations](https://www.ncpe.ie/pharmacoeconomic-evaluations/) - The NCPE conducts health technology assessments (HTA) of drugs and other health technologies in Ireland
- [Reports](https://www.ncpe.ie/publications/reports/) - Summary reports of NCPE pharmacoeconomic assessments are published on the NCPE website under Pharmacoeconomic Evaluations
- [Publications](https://www.ncpe.ie/publications/) - NCPE research has been published in numerous peer-reviewed papers and presented at national and at international conferences on Health Technology Assessment and Pharmacoeconomics.
- [Generic Drug Utilisation Reports](https://www.ncpe.ie/research/generic-drug-utisation/)
- [Pharmacoeconomic Research](https://www.ncpe.ie/research/pharmacoeconomics/) - Pharmacoeconomic Research in the National Centre for Pharmacoeconomics
- [Useful Links](https://www.ncpe.ie/for-patients/useful-links/)
- [Patient Education](https://www.ncpe.ie/for-patients/patient-education/)
- [NCPE recommendations](https://www.ncpe.ie/submission-process/public-consultation-2/)
- [Patient Submission Template](https://www.ncpe.ie/submission-process/submission-templates/patient-submission-template/)
- [News](https://www.ncpe.ie/news/)
- [Development of the Patient Organisation Submission Process in the NCPE](https://www.ncpe.ie/for-patients/patient-submission-process-overview/development-of-the-patient-organisation-submission-process-in-the-ncpe/)
- [example](https://www.ncpe.ie/example/)
- [Drugs](https://www.ncpe.ie/pharmacoeconomic-evaluations/all-drug/)
- [Latest Drugs](https://www.ncpe.ie/pharmacoeconomic-evaluations/all-drug/drugs/)
- [Diagnostics and Other Technologies](https://www.ncpe.ie/pharmacoeconomic-evaluations/vaccines-and-other-technologies/)
- [Vaccines](https://www.ncpe.ie/pharmacoeconomic-evaluations/vaccines/)
- [Archive](https://www.ncpe.ie/pharmacoeconomic-evaluations/archive/)
- [Sitemap](https://www.ncpe.ie/sitemap/)
- [Glossary](https://www.ncpe.ie/glossary/)

## Categories

- [Uncategorized](https://www.ncpe.ie/category/uncategorized/)
- [Drugs](https://www.ncpe.ie/category/drugs/)
- [News](https://www.ncpe.ie/category/news/)
- [Glossary](https://www.ncpe.ie/category/glossary/)
- [N](https://www.ncpe.ie/category/glossary/n/)
- [Featured](https://www.ncpe.ie/category/featured/)
- [A](https://www.ncpe.ie/category/drugs/a-drugs/)
- [F](https://www.ncpe.ie/category/drugs/f-drugs/)
- [D](https://www.ncpe.ie/category/drugs/d/)
- [T](https://www.ncpe.ie/category/drugs/t/)
- [A](https://www.ncpe.ie/category/glossary/a-glossary/)
- [Diagnostic](https://www.ncpe.ie/category/diagnostic/)
- [Vaccines](https://www.ncpe.ie/category/vaccines/)
- [C](https://www.ncpe.ie/category/glossary/c/)
- [B](https://www.ncpe.ie/category/glossary/b/)
- [D](https://www.ncpe.ie/category/glossary/d-glossary/)
- [E](https://www.ncpe.ie/category/glossary/e/)
- [H](https://www.ncpe.ie/category/glossary/h/)
- [I](https://www.ncpe.ie/category/glossary/i/)
- [M](https://www.ncpe.ie/category/glossary/m/)
- [O](https://www.ncpe.ie/category/glossary/o/)
- [P](https://www.ncpe.ie/category/glossary/p/)
- [Q](https://www.ncpe.ie/category/glossary/q/)
- [R](https://www.ncpe.ie/category/glossary/r/)
- [S](https://www.ncpe.ie/category/glossary/s/)
- [T](https://www.ncpe.ie/category/glossary/t-glossary/)
- [U](https://www.ncpe.ie/category/glossary/u/)
- [V](https://www.ncpe.ie/category/glossary/v/)
- [W](https://www.ncpe.ie/category/glossary/w/)
- [R](https://www.ncpe.ie/category/drugs/r-drugs/)
- [I](https://www.ncpe.ie/category/drugs/i-drugs/)
- [S](https://www.ncpe.ie/category/drugs/s-drugs/)
- [V](https://www.ncpe.ie/category/drugs/v-drugs/)
- [B](https://www.ncpe.ie/category/drugs/b-drugs/)
- [G](https://www.ncpe.ie/category/drugs/g/)
- [L](https://www.ncpe.ie/category/drugs/l/)
- [K](https://www.ncpe.ie/category/drugs/k/)
- [U](https://www.ncpe.ie/category/drugs/u-drugs/)
- [P](https://www.ncpe.ie/category/drugs/p-drugs/)
- [M](https://www.ncpe.ie/category/drugs/m-drugs/)
- [C](https://www.ncpe.ie/category/drugs/c-drugs/)
- [N](https://www.ncpe.ie/category/drugs/n-drugs/)
- [E](https://www.ncpe.ie/category/drugs/e-drugs/)
- [O](https://www.ncpe.ie/category/drugs/o-drugs/)
- [H](https://www.ncpe.ie/category/drugs/h-drugs/)
- [Z](https://www.ncpe.ie/category/drugs/z/)
- [Latest NCPE Advice](https://www.ncpe.ie/category/latest-ncpe-advice/)
- [Q](https://www.ncpe.ie/category/drugs/q-drugs/)